



(51) International Patent Classification:

A61K 31/522 (2006.01) A61K 31/7076 (2006.01)

(21) International Application Number:

PCT/US2017/034706

(22) International Filing Date:

26 May 2017 (26.05.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/342,593 27 May 2016 (27.05.2016) US

(71) Applicants: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US). THE WISTAR INSTITUTE [US/US]; 3601 Spruce Street, Philadelphia, PA 19104 (US).

(72) Inventors: SHAY, Jerry, W.; 5060 Horseshoe Trail, Dallas, TX 75209 (US). ZHANG, Gao; 418 South 45th Street, Apt. 1R, Philadelphia, PA 19104 (US).

(74) Agent: HIGHLANDER, Steven, L.; Parker Highlander PLLC, 1120 S. Capital of Texas Highway, Building One, Suite 200, Austin, TX 78746 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: 6-THIO-2'-DEOXYGUANOSINE (6-THIO-DG) RESULTS IN TELOMERASE DEPENDENT TELOMERE DYSFUNCTION AND CELL DEATH IN THERAPY-RESISTANT CANCER CELLS

(57) Abstract: The present disclosure provide for methods of using 6-thio-2'-deoxyguanosine (6-thio- dG) to treat telomerase-positive cancers that exhibit (a) one or more TERT promoter mutations, and/or (b) enriched telomere transcriptional signature(s). In particular, melanomas, including those who are not sensitive or have become resistant to immune checkpoint inhibition and/or MAPKi therapy are targets for this therapy.



DESCRIPTION**6-THIO-2'-DEOXYGUANOSINE (6-THIO-DG) RESULTS IN TELOMERASE
DEPENDENT TELOMERE DYSFUNCTION AND CELL DEATH IN VARIOUS
MODELS OF THERAPY-RESISTANT CANCER CELLS****PRIORITY CLAIM**

This application claims benefit of priority to U.S. Provisional Application Serial No. 62/342,593, filed May 27, 2016, the entire contents of which are hereby incorporated by reference.

5

BACKGROUND**I. Field**

The present disclosure relates to the fields of medicine, pharmacology and oncology. More particular, the disclosure relates to methods and compositions for treating cancers that express telomerase, a cellular reverse transcriptase that is express in 90% of all human cancers.

10 In some embodiments, the cancer is melanoma.

II. Related Art

Telomerase promoter mutations are highly prevalent in human tumors including melanoma. Telomere transcriptional signatures are enriched in a subset of therapy-naïve melanomas associated with worse overall survival, in *BRAF*-mutant intrinsically resistant
15 melanoma cells that evade MAPK inhibitors (MAPKi), as well as in a subset of post-treatment tumor biopsies derived from patients who have disease progression on MAPKi or the immune checkpoint inhibitors. Herein, the efficacy of a telomerase-directed nucleoside, 6-thio-2'-deoxyguanosine (6-thio-dG) that results in telomere dysfunction and cell death in various models of therapy-resistant cells, is demonstrated. Furthermore, 6-thio-dG significantly
20 inhibits tumor growth of primary tumor biopsy cultures derived from patients who had disease progression on multiple therapies including anti-CTLA-4 or anti-PD1.

Immune checkpoint blockade inhibitors and mitogen-activated protein kinase (MAPK) inhibitors have emerged as first-line therapies for patients with advanced melanomas. Despite highly encouraging successes, many patients do not respond and even those that do initially
25 respond, many patients ultimately relapse and are left with limited options. As a result, there is an unmet and urgent need to prolong disease control for patients who fail multiple therapies.

SUMMARY

Thus, in accordance with the present disclosure, there is provided a method of treating a subject with cancer comprising administering to said subject a therapeutically effective amount of 6-thio-2'-deoxyguanosine (6-thio-dG), wherein cells of said cancer are telomerase-positive and exhibit (a) one or more *TERT* promoter mutations, and/or (b) enriched telomere transcriptional signature(s). Also provided is a method of treating a subject with melanoma comprising administering to said subject a therapeutically effective amount of 6-thio-2'-deoxyguanosine (6-thio-dG), wherein melanoma is resistant to an immunotherapy and/or MAPKi therapy.

The subject may have had disease progression during or after platinum-based therapy, radiotherapy, immunotherapy and/or MAPKi therapy. The immunotherapy may be an immune checkpoint inhibitor, such as anti-CTLA4 therapy or anti-PD1 therapy. The MAPKi therapy may be an anti-MEK therapy, an anti-Raf therapy, and anti-p38 MAPK therapy, and anti-JNK therapy, and anti-ERK therapy, or an anti MNK therapy, such as vemurafenib, sorafenib, dabrafenib, trametinib, selumetinib, losapimod, GSK2118436, PD0325901, PLX4032 or PLX4720. The cancer may be a B-Raf-mutated cancer, such as a *Braf*^{V600} mutant. The cancer may be a lung cancer, a melanoma, pancreatic cancer or an ovarian cancer. The cancer may be recurrent, metastatic and/or multi-drug resistant.

The enriched telomere transcription signature may be a telomere maintenance signature or a packaging of telomere ends signature. The therapeutically effective amount of 6-thio-dG may be between about 0.5 mg/kg and 5.0 mg/kg. The 6-thio-dG is administered more than once, such as twice daily, daily, every other day, twice a week, weekly, every other week, every three weeks, or monthly. The 6-thio-dG is administered systemically, such as orally or intravenously, or administered intratumorally, or local or regional to a tumor site. The subject may be a human subject or a non-human mammalian subject.

The method may further comprise treating said subject with a second cancer therapy, such as an immunotherapy, such as ipilimumab and nivolumab or combination of ipilimumab and nivolumab, a radiotherapy, a neoadjuvant chemotherapy (such as platinum/taxane), a toxin therapy, a hormonal therapy or surgery. The second cancer therapy may be administered at the same time or after 6-thio-dG, or may be administered before 6-thio-dG.

The treatment may result in one or more of impaired cancer cell viability, cancer cell apoptosis, cancer cell senescence in surviving cancer cells, and progressively shortened telomeres in surviving cancer cells. The treatment may result in one or more of increased

subject survival, reduced tumor burden, reduction in primary tumor size, reduced metastasis, induction of remission, reduced subject hospitalization and increased subject comfort.

The method may further comprise assessing a cancer cell from said subject from one or more of (a) *TERT* promoter mutations, (b) enriched telomere transcriptional signature(s), (c) 5 increased AXL expression, (d) increased PDGFR β expression, and/or (e) one or more B-Raf mutations. The enriched telomere transcription signature may be a telomere maintenance signature or a packaging of telomere ends signature.

It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein.

10 The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”

These, and other, embodiments of the disclosure will be better appreciated and understood when considered in conjunction with the following description and the 15 accompanying drawings. It should be understood, however, that the following description, while indicating various embodiments of the disclosure and numerous specific details thereof, is given by way of illustration and not of limitation. Many substitutions, modifications, additions and/or rearrangements may be made within the scope of the disclosure without departing from the spirit thereof, and the disclosure includes all such substitutions, 20 modifications, additions and/or rearrangements.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

FIGS. 1A-1B show long-term cell growth assay of 12 non-melanoma cancer cell lines (FIG. 1A) and 12 BRAF-mutant melanoma cell lines (FIG. 1B) that were treated with 6-thio-dG (6dG) or BIBR 1532 (BIBR) at indicated doses for 9 to 12 days. Cells were then fixed and stained with crystal violet. Representative image of 2 biological replicates were shown for each experimental condition.

FIG. 2 shows mutational frequencies of *TERT*, *BRAF* and *NRAS* in Wistar melanoma cell lines, Wistar PDX, Wistar PDX that are resistant to MAPKi and TCGA SKCM data sets.

FIGS. 3A-3E show long-term cell growth assay of 16 BRAF-mutant melanoma cell lines that were treated with 6-thio-dG or PLX4720 at indicated doses for 12 days (FIG. 3A). Cells were then fixed and stained with crystal violet. Representative image of 2 biological replicates were shown for each experimental condition; percentage of apoptotic and dead cells indicated as PSVue 643+ cells in 12 BRAF-mutant melanoma cell lines treated with PLX4720 or 6-thio-dG (FIG. 3B) or in the A375 cell line treated with 6-thio-dG (FIG. 3C) at indicated doses for 120 hours. Cells were then harvested and co-stained with PSVue643 and Propidium iodide (PI). The average of 2 biological replicates are representative of 2 independent experiments; SA- β -gal staining of 4 BRAF-mutant melanoma cell lines treated with 6-thio-dG at 5 μ M for 9 days (FIG. 3D). A representative image of 3 biological replicates was shown for each experimental sample; and tumor volumes of 1205Lu xenografts that were treated for 12 days with the vehicle control or 6-thio-dG at indicated doses (FIG. 3E).

FIG. 4 shows percentage of apoptotic and dead cells in normal skin melanocytes (upper panel) or keratinocytes (lower panel) that were treated with the vehicle control or 6-thio-dG at indicated doses for 120 hours. Cells were then harvested and co-stained with PSVue643 and Propidium iodide (PI). Representative samples of 2 independent experiments.

FIGS. 5A-5G show the heatmap of RNA-seq data depicting genes that were most significantly down-regulated in A375 cells treated with 6-thio-dG (6dG) or BIBR 1532 (BIBR) for 72 hours (FIG. 5A). 2 biological replicates were shown for each experimental condition; the plot of Biocarta gene sets that were most significantly altered in A375 cells treated with 6-

thio-dG (6dG) (FIG. 5B) or BIBR 1532 (BIBR) (FIG. 5C) as determined by the hypergeometric differential analysis; the ssGSEA plot of “Telomere” and “Cell Cycle” gene sets that were significantly altered in A375 cells treated with BIBR 1532 (BIBR) or 6-thio-dG (6dG) (FIG. 5D); the heatmap of RPPA data depicting 30 proteins that were most significantly down-regulated in A375 cells treated with 6-thio-dG (6dG) for 72 hours (FIG. 5E). 2 biological replicates were shown for each experimental condition; and Western blotting of proteins that were down-regulated in A375 cells treated with 6-thio-dG (6dG) for 48 and 72 hours (FIG. 5F) or 6-thio-dG (6dG), GRN163L (GRN) or BIBR 1532 (BIBR) for 48 hours (FIG. 5G) as identified by RPPA.

FIGS. 6A-6G show the heatmaps of RPPA data of ARID1A, AXL, PDGFR β and PLK1 for A375, UACC-903 and WM9 cells that were treated with the control or 6-thio-dG for 120 hours (FIG. 6A); Immunoblot analysis of proteins in samples shown in FIG. 6A (FIG. 6B); heatmaps of RPPA data of ARID1A, AXL, PDGFR β and PLK1 for A375 cells that were treated with the control or MAPKi at indicated doses for 120 hours (FIG. 6C); Immunoblot analysis of proteins in samples shown in (FIGS. 6C-6D) (FIG. 6E); the heatmaps of RPPA data of ARID1A, AXL, PDGFR β and PLK1 for A375, UACC-903 and WM9 parental cells and cells that acquired resistance to the BRAF inhibitor PLX4720 (BR) or cells that acquired resistance to the combination of PLX4720 and the MEK inhibitor PD0325901 (CR) (FIG. 6F); and long-term cell growth assay of 3 BRAF-mutant melanoma cell lines treated with 6-thio-dG at 5 μ M and the BRAF inhibitor GSK2118436 at 1 μ M either as single agent or in combination for 15 days. Ctrl: the vehicle control (FIG. 6G).

FIGS. 7A-7L show percentage of apoptotic and dead cells indicated as PSVue 643+ cells for LOX-IMVI BR cells that were treated with the control or 6-thio-dG at indicated doses for 120 hours (FIG. 7A). The average of 2 biological replicates was plotted, and data are representative of 2 independent experiments; the telomere length was measured in samples treated with 6-thio-dG at 0 and 5 μ M as shown in FIG. 7A (FIG. 7B); co-staining of γ -H2AX antibody (double strand DNA damage marker) with an in situ telomere specific hybridization probe (FITC-conjugated telomere sequence (TTAGGG)₃ peptide nucleic acid) in samples shown in FIG. 7B (FIG. 7C); quantification of DNA damage foci (FIG. 7D) and TIF (FIG. 7E) for samples shown in FIG. 7C; the ssGSEA plot of “Telomere” and “Cell Cycle” gene sets that were significantly altered in LOX-IMVI BR cells treated with BIBR 1532 (BIBR) or 6-thio-dG (6dG) (FIG. 7F); the heatmap of RPPA data depicting 30 proteins that were most significantly down-regulated in LOX-IMVI BR cells treated with 6-thio-dG (6dG) for 72 hours (FIG. 7G) (2 biological replicates were shown for each experimental condition); Immunoblot

analysis of AXL and PLK1 for LOX-IMVI BR cells treated with the control or 6-thio-dG for 120 hours (FIG. 7H); long-term cell growth assay of 7 melanoma cell lines that acquired resistance to MAPKi treated with 6-thio-dG at indicated doses for 12 days (FIG. 7I) (Cells were then fixed and stained with crystal violet. A representative image of 2 biological replicates is shown for each experimental condition); and tumor volumes of xenografts of WM9 BR (FIG. 7J), LOX-IMVI BR (FIG. 7K) and UACC-903 BR (FIG. 7L) cells that were treated with the vehicle control or 6-thio-dG.

FIGS. 8A-8D show long-term cell growth assay of 4 melanoma cell lines that acquired resistance to MAPKi treated with 6-thio-dG at indicated doses for 12 days (FIG. 8A) (Cells were then fixed and stained with crystal violet. A representative image of 2 biological replicates is shown for each experimental condition); the heatmaps of RPPA data depicting 30 proteins that were most significantly down-regulated in eight BR cell lines (FIG. 8B), 1205Lu xenografts (FIG. 8C) and UACC-903 BR and LOX-IMVI BR xenografts (FIG. 8D) treated with 6-thio-dG.

FIGS. 9A-9F show the heatmap of enrichment scores of six gene sets in TCGA melanoma (FIG. 9A) and normal skin, nevi, and melanoma (FIG. 9B); Kaplan-Meier survival curves for TCGA melanoma cases which were divided into 2 subgroups with high and low enrichment scores of two telomere transcriptional gene sets (FIG. 9C); the heatmap of two telomere transcriptional gene signatures, two melanoma-specific gene sets and two MAPK pathway-related gene sets in GSE61992 in which transcriptomes of patients' paired pre- and post-treatment tumor biopsies were profiled (FIG. 9D); the GSEA plot of the "Biocarta Tel Pathway" gene set that was enriched in post-treatment tumor biopsies derived from patients Memorial Sloan Kettering Cancer Center who did not experience long-term benefit from ipilimumab (FIG. 9E); the GSEA plot of the "Telomere Maintenance" (upper panel) and "Packaging of Telomere Ends" (lower panel) gene sets that were enriched in the on-treatment tumor biopsy derived from a patient (ID #39) at Massachusetts General Hospital who did not experience long-term benefit from pembrolizumab (FIG. 9F).

FIGS. 10A-10D show the heatmaps of two telomere transcriptional gene signatures (FIG. 10A), two melanoma-specific gene sets (FIG. 10B), and two MAPK pathway-related gene sets (FIG. 10C) in three datasets in which transcriptomes of paired pre- and post-treatment tumor biopsies derived from patients who progressed on MAPKi were profiled. Expression of TERT transcript was determined by quantitative PCR experiment in paired pre-, on- and post-treatment tumor biopsies derived from patients who were treated with MAPKi at Massachusetts General Hospital (FIG. 10D).

FIG. 11 shows the heatmaps of two telomere transcriptional gene signatures, two melanoma-specific gene sets and two MAPK pathway-related gene sets in three datasets in which transcriptomes of paired pre- and post-treatment tumor biopsies derived from 12 patients who were treated with immune checkpoint blockade therapies were profiled.

FIGS. 12A-12I show long-term cell growth assay of 6 patient- or mouse-derived cultures that were treated with 6-thio-dG at indicated doses for 12 days (**FIG. 12A**) (Cells were then fixed and stained with crystal violet. A representative image of 2 biological replicates is shown for each experimental sample); tumor volumes of xenografts of 5 patient- or mouse-derived cultures treated with the vehicle control or 6-thio-dG (**FIGS. 12B-12F**); the heatmap of RPPA data depicting 30 proteins that were most significantly down-regulated in xenografts of 13-456-5-3 (**FIG. 12G**), 13-456-3-3 (**FIG. 12H**) and WM4265-2 (**FIG. 12I**) treated with 6-thio-dG (6dG).

FIG. 13 shows the heatmaps of RPPA data depicting 30 proteins that were most significantly down-regulated in 13-456-3-3, 13-456-5-3, WM4265-1 and WM4265-2 cells treated with 6-thio-dG.

FIGS. 14A-14M show long-term cell growth assay of G43 cells treated with 6-thio-dG at indicated doses for 12 days (**FIG. 14A**) (Cells were then fixed and stained with crystal violet. A representative image of 2 biological replicates is shown for each experimental condition); tumor volume of xenografts of G43 cells treated with the vehicle control or 6-thio-dG (**FIG. 14B**); the heatmap of RPPA data depicting 30 proteins that were most significantly down-regulated in G43 cells treated with 6-thio-dG *in vitro* (**FIG. 14C**) or G43 tumors treated with 6-thio-dG *in vivo* (**FIG. 14D**); the relative cell viability of PEO1 and PEO1-derived cell lines treated with carboplatin (Carbo) or 6-thio-dG at indicated doses for 5 days (**FIGS. 14E-14J**); Immunofluorescence staining of the patient-derived culture WO-24-2 with anti-PAX8 (red) and cytokeratin 7 (green) (**FIG. 14K**); and the relative cell viability of the patient-derived culture WO-24-2 treated with carboplatin (Carbo) (**FIG. L**) or 6-thio-dG (**FIG. M**) at indicated doses for 5 days.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

In telomerase-positive melanoma cells with a high frequency of *TERT* promoter mutations, the present inventors herein demonstrate that 6-thio-dG exhibits strong anti-tumor effects by concomitantly inducing telomere dysfunction and inhibiting ARID1A, AXL, PDGFR β and PLK1. 6-thio-dG not only abrogates intrinsic and acquired drug resistance to MAPK inhibitors, but also inhibits the growth of tumors that have become resistant to immune checkpoint blockade therapies. Furthermore, the efficacy of 6-thio-dG in therapy-resistant mouse pancreatic cancer and human ovarian cancer cells is demonstrated. Thus, 6-thio-dG presents a viable approach to prolonged disease control of therapy-resistant tumors as an effective salvage therapy. These and other aspects of the disclosure are set out in detail below.

I. Telomerase and Telomere Dysfunction

During mitosis, cells make copies of their genetic material. Half of the genetic material goes to each new daughter cell. To make sure that information is successfully passed from one generation to the next, each chromosome has a special protective cap called a telomere located at the end of its “arms.” Telomeres are controlled by the presence of the enzyme telomerase.

A telomere is a repeating DNA sequence (for example, TTAGGG) at the end of the body's chromosomes. The telomere can reach a length of 15,000 base pairs. Telomeres function by preventing chromosomes from losing base pair sequences at their ends. They also stop chromosomes from fusing to each other. However, each time a cell divides, some of the telomere is lost (usually 25-200 base pairs per division). When the telomere becomes too short, the chromosome reaches a “critical length” and can no longer replicate. This means that a cell becomes old and dies by a process called apoptosis. Telomere activity is controlled by two mechanisms: erosion and addition. Erosion, as mentioned, occurs each time a cell divides. Addition is determined by the activity of telomerase.

Telomerase, also called telomere terminal transferase, is an enzyme made of protein and RNA subunits that elongates chromosomes by adding TTAGGG sequences to the end of existing chromosomes. Telomerase is found in fetal tissues, adult germ cells, and also tumor cells. Telomerase activity is regulated during development and has a very low, almost undetectable activity in somatic (body) cells. Because these somatic cells do not regularly use telomerase, they age. The result of aging cells is an aging body. If telomerase is activated in a cell, the cell will continue to grow and divide. This “immortal cell” theory is important in two areas of research: aging and cancer.

Cellular aging, or senescence, is the process by which a cell becomes old and dies. It is due to the shortening of chromosomal telomeres to the point that the chromosome reaches a critical length. Cellular aging is analogous to a wind up clock. If the clock stays wound, a cell becomes immortal and constantly produces new cells. If the clock winds down, the cell stops producing new cells and dies. Cells are constantly aging. Being able to make the body's cells live forever certainly creates some exciting possibilities. Telomerase research could therefore yield important discoveries related to the aging process.

Cancer cells are a type of malignant cell. The malignant cells multiply until they form a tumor that grows uncontrollably. Telomerase has been detected in human cancer cells and is found to be 10-20 times more active than in normal body cells. This provides a selective growth advantage to many types of tumors. If telomerase activity was to be turned off, then telomeres in cancer cells would shorten, just like they do in normal body cells. This would prevent the cancer cells from dividing uncontrollably in their early stages of development. In the event that a tumor has already thoroughly developed, it may be removed and anti-telomerase therapy could be administered to prevent relapse. In essence, preventing telomerase from performing its function would change cancer cells from immortal to mortal.

II. MAPK Inhibition

A mitogen-activated protein kinase (MAPK or MAP kinase) is a type of protein kinase that is specific to the amino acids serine, threonine, and tyrosine (*i.e.*, a serine/threonine-specific protein kinase). MAPKs are involved in directing cellular responses to a diverse array of stimuli, such as mitogens, osmotic stress, heat shock and pro-inflammatory cytokines. They regulate cell functions including proliferation, gene expression, differentiation, mitosis, cell survival, and apoptosis.

MAP kinases are found in eukaryotes only, but they are fairly diverse and encountered in all animals, fungi and plants, and even in an array of unicellular eukaryotes. MAPKs belong to the CMGC (CDK/MAPK/GSK3/CLK) kinase group. The closest relatives of MAPKs are the cyclin-dependent kinases (CDKs).

Since the ERK signaling pathway is involved in both physiological and pathological cell proliferation, it is natural that ERK1/2 inhibitors would represent a desirable class of antineoplastic agents. Indeed, many of the proto-oncogenic "driver" mutations are tied to ERK1/2 signaling, such as constitutively active (mutant) receptor tyrosine kinases, Ras or Raf proteins. Although no MKK1/2 or ERK1/2 inhibitors were developed for clinical use, kinase

inhibitors that also inhibit Raf kinases (*e.g.*, Sorafenib) are successful antineoplastic agents against various types of cancer.

JNK kinases are implicated in the development of insulin resistance in obese individuals as well as neurotransmitter excitotoxicity after ischemic conditions. Inhibition of JNK1 ameliorates insulin resistance in certain animal models. Mice that were genetically engineered to lack a functional JNK3 gene - the major isoform in brain - display enhanced ischemic tolerance and stroke recovery. Although small-molecule JNK inhibitors are under development, none of them proved to be effective in human tests yet. Interestingly, a peptide-based JNK inhibitor (AM-111, a retro-inverse D-motif peptide from JIP1, formerly known as XG-102) is also under clinical development for sensorineural hearing loss.

p38 was once believed to be a perfect target for anti-inflammatory drugs. Yet the failure of more than a dozen chemically different compounds in the clinical phase suggests that p38 kinases might be poor therapeutic targets in autoimmune diseases. Many of these compounds were found to be hepatotoxic to various degree and tolerance to the anti-inflammatory effect developed within weeks.

III. Immune Checkpoint Inhibition

Immune checkpoints are molecules in the immune system that either turn up a signal (co-stimulatory molecules) or turn down a signal. Many cancers protect themselves from the immune system by inhibiting the T cell signal. Since around 2010 inhibitory checkpoint molecules have been increasingly considered as new targets for cancer immunotherapies due to the effectiveness of two checkpoint inhibitor drugs that were initially indicated for advanced melanoma – Yervoy®, from Bristol-Myers Squibb, and Keytruda®, from Merck.

Four stimulatory checkpoint molecules are members of the tumor necrosis factor (TNF) receptor superfamily - CD27, CD40, OX40, GITR and CD137. Another two stimulatory checkpoint molecules belongs to the B7-CD28 superfamily - CD28 itself and ICOS.

CD27. This molecule supports antigen-specific expansion of naïve T cells and is vital for the generation of T cell memory. CD27 is also a memory marker of B cells. CD27's activity is governed by the transient availability of its ligand, CD70, on lymphocytes and dendritic cells. CD27 costimulation is known to suppress Th17 effector cell function. The American biotech company Celldex Therapeutics is working on CDX-1127, an agonistic anti-CD27 monoclonal antibody which in animal models has been shown to be effective in the context of T cell receptor stimulation.

CD28. This molecule is constitutively expressed on almost all human CD4+ T cells and on around half of all CD8 T cells. Binding with its two ligands are CD80 and CD86, expressed on dendritic cells, prompts T cell expansion. CD28 was the target of the TGN1412 ‘superagonist’ which caused severe inflammatory reactions in the first-in-man study in London
5 in March 2006.

CD40. This molecule, found on a variety of immune system cells including antigen presenting cells has CD40L, otherwise known as CD154 and transiently expressed on the surface of activated CD4+ T cells, as its ligand. CD40 signaling is known to ‘license’ dendritic cells to mature and thereby trigger T-cell activation and differentiation. A now-defunct Seattle-
10 based biotechnology company called VLST in-licensed an anti-CD40 agonist monoclonal antibody from Pfizer in 2012. The Swiss pharmaceutical company Roche acquired this project when VLST was shut down in 2013.

CD122. This molecule, which is the Interleukin-2 receptor beta sub-unit, is known to increase proliferation of CD8+ effector T cells. The American biotechnology company Nektar
15 Therapeutics is working on NKTR-214, a CD122-biased immune-stimulatory cytokine Phase I results announced in Nov 2016.

CD137. When this molecule, also called 4-1BB, is bound by CD137 ligand, the result is T-cell proliferation. CD137-mediated signaling is also known to protect T cells, and in particular, CD8+ T cells from activation-induced cell death. The German biotech company
20 Pieris Pharmaceuticals has developed an engineered lipocalin that is bi-specific for CD137 and HER2.

OX40. This molecule, also called CD134, has OX40L, or CD252, as its ligand. Like CD27, OX40 promotes the expansion of effector and memory T cells, however it is also noted for its ability to suppress the differentiation and activity of T-regulatory cells, and also for its
25 regulation of cytokine production. OX40's value as a drug target primarily lies in the fact that, being transiently expressed after T-cell receptor engagement, it is only upregulated on the most recently antigen-activated T cells within inflammatory lesions. Anti-OX40 monoclonal antibodies have been shown to have clinical utility in advanced cancer.³ The pharma company AstraZeneca has three drugs in development targeting OX40: MEDI0562 is a humanized OX40
30 agonist; MEDI6469, murine OX4 agonist; and MEDI6383, an OX40 agonist.

GITR (Glucocorticoid-Induced TNFR Family Related Gene). GITR prompts T cell expansion, including Treg expansion. The ligand for GITR is mainly expressed on antigen presenting cells. Antibodies to GITR have been shown to promote an anti-tumor response

through loss of Treg lineage stability. The biotech company TG Therapeutics is working on anti-GITR antibodies.

ICOS. This molecule, short for Inducible T-cell costimulator, and also called CD278, is expressed on activated T cells. Its ligand is ICOSL, expressed mainly on B cells and dendritic cells. The molecule seems to be important in T cell effector function. The American biotechnology company Jounce Therapeutics is developing an ICOS agonist.

A2AR. The Adenosine A2A receptor is regarded as an important checkpoint in cancer therapy because adenosine in the immune microenvironment, leading to the activation of the A2a receptor, is negative immune feedback loop and the tumor microenvironment has relatively high concentrations of adenosine.

B7-H3 (CD276). B7-H3 was originally understood to be a co-stimulatory molecule but is now regarded as co-inhibitory. The American biotechnology company MacroGenics is working on MGA271 is an Fc-optimized monoclonal antibody that targets B7-H3. B7-H3's receptors have not yet been identified.

B7-H4 (VTCN1). This molecule is expressed by tumor cells and tumor-associated macrophages and plays a role in tumor escape.

BTLA. This molecule, short for B and T Lymphocyte Attenuator and also called CD272, has HVEM (Herpesvirus Entry Mediator) as its ligand. Surface expression of BTLA is gradually downregulated during differentiation of human CD8+ T cells from the naive to effector cell phenotype, however tumor-specific human CD8+ T cells express high levels of BTLA.

CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4; CD152). This molecule is the target of Bristol-Myers Squibb's melanoma drug Yervoy®, which gained FDA approval in March 2011. Expression of CTLA-4 on Treg cells serves to control T cell proliferation.

IDO (Indoleamine 2,3-dioxygenase). This is a tryptophan catabolic enzyme with immune-inhibitory properties. Another important molecule is TDO, tryptophan 2,3-dioxygenase. IDO is known to suppress T and NK cells, generate and activate Tregs and myeloid-derived suppressor cells, and promote tumour angiogenesis. The American biotechnology companies Newlink Genetics and Incyte are working on IDO pathway inhibitors.

KIR (Killer-cell Immunoglobulin-like Receptor). This is a receptor for MHC Class I molecules on Natural Killer cells. Bristol-Myers Squibb is working on Lirilumab, a monoclonal antibody to KIR.

LAG3 (Lymphocyte Activation Gene-3) works to suppress an immune response by action to Tregs as well as direct effects on CD8+ T cells. Bristol-Myers Squibb is in Phase I with an anti-LAG3 monoclonal antibody called BMS-986016.

PD-1 (Programmed Death 1 (PD-1) receptor). PD-1 has two ligands, PD-L1 and PD-L2. This checkpoint is the target of Keytruda®, which gained FDA approval in September 2014. An advantage of targeting PD-1 is that it can restore immune function in the tumor microenvironment.

TIM-3 (T-cell Immunoglobulin domain and Mucin domain 3). TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. TIM-3 acts as a negative regulator of Th1/Tc1 function by triggering cell death upon interaction with its ligand, galectin-9.

VISTA. Short for V-domain Ig suppressor of T cell activation, VISTA is primarily expressed on hematopoietic cells so that consistent expression of VISTA on leukocytes within tumors may allow VISTA blockade to be effective across a broad range of solid tumors.

IV. Therapies

A. Target Cancers

In accordance with the present disclosure, 6-thio-dG can be employed to treat a variety of cancer types. In general, melanomas, lung cancers, pancreatic cancers and ovarian cancers. However, more generally, tumors expressing telomerase, including those having *TERT* promoter mutations and enriched telomere transcription signatures (*e.g.*, a telomere maintenance signature and/or a packaging of telomere ends signature). Moreover, a variety of therapy-resistant cancers are responsive to 6-thio-dG therapy.

By way of background, the inventors examined publically available databases and found that patients with telomerase mutations and telomere transcriptional signature had overall worse survival in a variety of types of advanced melanoma (such as those with BRAF mutations). The inventors hypothesized that patients having failed BRAF inhibitor therapy, such as MAPK inhibitors (downstream of BRAF activating mutations), would be good candidates for 6-thio-dG therapy. This would be important given that patients that fail MAPKi have few therapeutic options remaining. The inventors examined cells from patients that failed MAPKi and found they were very sensitive to 6-thio-dG. Moreover, over 50% of advanced

melanoma patients do not respond to immunotherapy, including powerful MAPKi and immune checkpoint therapies, leaving a major gap in therapeutic options that can be filled by 6-thio-dG.

Melanoma is in particular of interest here. It is known that *TERT* promoter mutations are very common in melanoma, as are enriched telomere transcriptional signatures. For example, the inventors have performed targeted sequencing that revealed a high frequency of *TERT* promoter mutations that are identified in 73.2% of 97 Wistar's melanoma cell lines, 67.4% of 172 Wistar's melanoma treatment-naïve PDXs, and 82.9% of 35 Wistar's MAPK inhibitors-resistant PDXs (data not shown), which is consistent with the finding that *TERT* promoter mutations occur in 64.3% of 115 TCGA melanoma patients. Notably, the frequency of *TERT* promoter mutations is significantly higher in Wistar's MAPK inhibitors-resistant PDXs than that in the TCGA melanoma patient cohort (Fisher's exact test; $p = 0.04$). Thus, melanoma is considered a prime target for 6-thio-dG therapy.

Skin cancer is the most common form of cancer in the U.S., and melanoma is the deadliest form of skin cancer. Over half of the people in the U.S. diagnosed with melanoma will be diagnosed with invasive (Stage I, II, III or IV). Melanoma is the leading cause of cancer death in young women ages 25-30, and the second leading cause of cancer death in women ages 30-35. In ages 15-29, melanoma is the second most commonly diagnosed cancer. The incidence of people under 30 developing melanoma is increasing faster than any other demographic group, soaring by 50% in women since 1980.

Commonly prescribed immune stimulants for the treatment of melanoma include biologic agents such as antibodies, interferons and interleukins, which are administered in much higher doses than are usually present in the body.

T-VEC (Imlygic®) received FDA approval in October 2015. Imlygic is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients whose melanoma has recurred after initial surgery. Imlygic is a genetically modified herpes simplex virus type 1 designed to replicate within tumors, causing tumors to rupture (cell death).

Ipi + Nivo (Ipilimumab® + Nivolumab®) combination received accelerated FDA approval in September 2015 based on improved response rates and progression-free survival in previously treated patients.

Nivolumab (Opdivo®) was approved in November 2015 as a first line therapy (previously untreated) for melanoma patients who do not have a positive BRAF V600 mutation. It was previously approved in 2014 for patients whose disease had progressed following ipilimumab and, if BRAF V600 mutation positive, also a BRAF inhibitor. It is the

second anti-PD-1 drug to be approved for the treatment of unresectable (cannot be removed by surgery) or advanced (metastatic) melanoma, but the only anti-PD-1 therapy approved as a single agent for first-line use in patients with advanced BRAF V600 wild-type (not mutated) melanoma.

5 Pembrolizumab (Keytruda®) received accelerated approval in 2014 for demonstrating durable responses in patients whose disease has progressed following ipilimumab and, if BRAF V600 mutation positive, also a BRAF inhibitor. Randomized trials are in progress to assess the ability of pembrolizumab to improve time to progression and overall survival. Keytruda is the first anti-PD-1 drug to be approved by the FDA for melanoma.

10 Ipilimumab (Yervoy®), which stimulates T cells, was approved by the FDA in 2011. It was the first drug in 13 years to be approved for the treatment of metastatic melanoma. Randomized trials have shown an improvement in overall survival in patients with either previously treated or untreated advanced melanoma. In addition, in October 2015, Yervoy was approved as adjuvant therapy in patients with Stage III melanoma. Patients and physicians
15 should be aware that immune-mediated toxicities may be severe so good communication with your physician will allow early identification and successful treatment. Common side effects include: tiredness, diarrhea, itching and rash.

 Peginterferon alpha 2-b (Sylatron®) is the FDA-approved standard treatment for patients with metastatic melanoma that has been surgically resected and that are at high risk
20 for recurrence (*i.e.*, for adjuvant therapy). Analyses of randomized trials of interferon used in an adjuvant setting show that it can lengthen the time of melanoma recurrence, but it does not appear to prolong survival.

 Interleukin-2 (IL-2; Proleukin®) was the first immunotherapy to be approved for metastatic melanoma (1998) and was approved on the basis of long-lasting complete response.
25 Randomized trials of IL-2 have not been conducted, so precise information on long-term overall survival is not available.

 Any of the preceding may be used prior to 6-thio-dG, even if the patient has progress, and/or may be used in combination with 6-thio-dG (see below).

30 B. Pharmaceutical Formulations and Routes of Administration

 Where clinical applications are contemplated, pharmaceutical compositions will be prepared in a form appropriate for the intended application. Generally, this will entail preparing compositions that are essentially free of pyrogens, as well as other impurities that could be harmful to humans or animals.

One will generally desire to employ appropriate salts and buffers to render drugs stable and allow for uptake by target cells. Aqueous compositions of the present invention comprise an effective amount of the drug dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium. The phrase “pharmaceutically or pharmacologically acceptable” refer to molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to an animal or a human. As used herein, “pharmaceutically acceptable carrier” includes solvents, buffers, solutions, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like acceptable for use in formulating pharmaceuticals, such as pharmaceuticals suitable for administration to humans. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredients of the present invention, its use in therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions, provided they do not inactivate the vectors or cells of the compositions.

The active compositions of the present invention may include classic pharmaceutical preparations. Administration of these compositions according to the present invention may be via any common route so long as the target tissue is available via that route, but generally including systemic administration. This includes oral, nasal, or buccal. Alternatively, administration may be by intradermal, subcutaneous, intramuscular, intraperitoneal or intravenous injection, intratumoral or by direct injection into muscle tissue. Such compositions would normally be administered as pharmaceutically acceptable compositions, as described *supra*.

The active compounds may also be administered parenterally or intraperitoneally. By way of illustration, solutions of the active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations generally contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include, for example, sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. Generally, these preparations are sterile and fluid to the extent that easy injectability exists. Preparations should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms, such as bacteria and fungi. Appropriate solvents or dispersion media may

contain, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.

5 The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum
10 monostearate and gelatin.

Sterile injectable solutions may be prepared by incorporating the active compounds in an appropriate amount into a solvent along with any other ingredients (for example as enumerated above) as desired, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which
15 contains the basic dispersion medium and the desired other ingredients, *e.g.*, as enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation include vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient(s) plus any additional desired ingredient from a previously sterile-filtered solution thereof.

20 The compositions of the present invention generally may be formulated in a neutral or salt form. Pharmaceutically-acceptable salts include, for example, acid addition salts (formed with the free amino groups of the protein) derived from inorganic acids (*e.g.*, hydrochloric or phosphoric acids, or from organic acids (*e.g.*, acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups of the protein can also be derived from inorganic
25 bases (*e.g.*, sodium, potassium, ammonium, calcium, or ferric hydroxides) or from organic bases (*e.g.*, isopropylamine, trimethylamine, histidine, procaine and the like.

Upon formulation, solutions are preferably administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations may easily be administered in a variety of dosage forms such as injectable solutions, drug
30 release capsules and the like. For parenteral administration in an aqueous solution, for example, the solution generally is suitably buffered and the liquid diluent first rendered isotonic for example with sufficient saline or glucose. Such aqueous solutions may be used, for example, for intravenous, intramuscular, subcutaneous and intraperitoneal administration. Preferably, sterile aqueous media are employed as is known to those of skill in the art,

particularly in light of the present disclosure. By way of illustration, a single dose may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologics standards.

C. Combination Therapies

In the context of the present disclosure, it also is contemplated 6-thio-dG could be used in conjunction with chemo- or radiotherapeutic intervention, or other treatments. It also may prove effective, in particular, to combine 6-thio-dG with other therapies that target different aspects of cancer cell function.

To kill cells, inhibit cell growth, inhibit metastasis, inhibit angiogenesis or otherwise reverse or reduce the malignant phenotype of tumor cells, using the methods and compositions of the present disclosure, one would generally contact a "target" cell with 6-thio-dG and at least one other agent. These compositions would be provided in a combined amount effective to kill or inhibit proliferation of the cell. This process may involve contacting the cells with 6-thio-dG and the other agent(s) or factor(s) at the same time. This may be achieved by contacting the cell with a single composition or pharmacological formulation that includes both agents, or by contacting the cell with two distinct compositions or formulations, at the same time, wherein one composition includes the interferon prodrugs according to the present disclosure and the other includes the other agent.

Alternatively, the 6-thio-dG therapy may precede or follow the other agent treatment by intervals ranging from minutes to weeks. In embodiments where the other agent and the interferon prodrugs are applied separately to the cell, one would generally ensure that a significant period of time did not expire between each delivery, such that the agent and expression construct would still be able to exert an advantageously combined effect on the cell. In such instances, it is contemplated that one would contact the cell with both modalities within about 12-24 hours of each other and, more preferably, within about 6-12 hours of each other, with a delay time of only about 12 hours being most preferred. In some situations, it may be desirable to extend the time period for treatment significantly, however, where several days (2,

3, 4, 5, 6 or 7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between the respective administrations.

It also is conceivable that more than one administration of either interferon prodrugs or the other agent will be desired. Various combinations may be employed, where 6-thio-dG therapy is “A” and the other therapy is “B”, as exemplified below:

A/B/A B/A/B B/B/A A/A/B B/A/A A/B/B B/B/B/A B/B/A/B
 A/A/B/B A/B/A/B A/B/B/A B/B/A/A B/A/B/A B/A/A/B B/B/B/A
 A/A/A/B B/A/A/A A/B/A/A A/A/B/A A/B/B/B B/A/B/B B/B/A/B

10

Other combinations are contemplated. Again, to achieve cell killing, both agents are delivered to a cell in a combined amount effective to kill the cell.

Agents or factors suitable for cancer therapy include any chemical compound or treatment method that induces DNA damage when applied to a cell. Such agents and factors include radiation and waves that induce DNA damage such as, irradiation, microwaves, electronic emissions, and the like. A variety of chemical compounds, also described as “chemotherapeutic” or “genotoxic agents,” may be used. This may be achieved by irradiating the localized tumor site; alternatively, the tumor cells may be contacted with the agent by administering to the subject a therapeutically effective amount of a pharmaceutical composition.

20

Various classes of chemotherapeutic agents are contemplated for use with the present disclosure. For example, selective estrogen receptor antagonists (“SERMs”), such as Tamoxifen, 4-hydroxy Tamoxifen (Afimoxfene), Falsodex, Raloxifene, Bazedoxifene, Clomifene, Femarelle, Lasofoxifene, Ormeloxifene, and Toremifene.

25

Chemotherapeutic agents contemplated to be of use, include, *e.g.*, camptothecin, actinomycin-D, mitomycin C. The disclosure also encompasses the use of a combination of one or more DNA damaging agents, whether radiation-based or actual compounds, such as the use of X-rays with cisplatin or the use of cisplatin with etoposide. The agent may be prepared and used as a combined therapeutic composition.

30

Heat shock protein 90 is a regulatory protein found in many eukaryotic cells. HSP90 inhibitors have been shown to be useful in the treatment of cancer. Such inhibitors include Geldanamycin, 17-(Allylamino)-17-demethoxygeldanamycin, PU-H71 and Rifabutin.

Agents that directly cross-link DNA or form adducts are also envisaged. Agents such as cisplatin, and other DNA alkylating agents may be used. Cisplatin has been widely used to

treat cancer, with efficacious doses used in clinical applications of 20 mg/m² for 5 days every three weeks for a total of three courses. Cisplatin is not absorbed orally and must therefore be delivered via injection intravenously, subcutaneously, intratumorally or intraperitoneally.

Agents that damage DNA also include compounds that interfere with DNA replication, 5 mitosis and chromosomal segregation. Such chemotherapeutic compounds include adriamycin, also known as doxorubicin, etoposide, verapamil, podophyllotoxin, and the like. Widely used in a clinical setting for the treatment of neoplasms, these compounds are administered through bolus injections intravenously at doses ranging from 25-75 mg/m² at 21 10 day intervals for doxorubicin, to 35-50 mg/m² for etoposide intravenously or double the intravenous dose orally. Microtubule inhibitors, such as taxanes, also are contemplated. These molecules are diterpenes produced by the plants of the genus *Taxus*, and include paclitaxel and docetaxel.

Epidermal growth factor receptor inhibitors, such as Iressa, mTOR, the mammalian target of rapamycin (also known as FK506-binding protein 12-rapamycin associated protein 1 15 (FRAP1)), is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, and transcription. Rapamycin and analogs thereof ("rapalogs") are therefore contemplated for use in cancer therapy in accordance with the present disclosure. Another EGFR inhibitor of particular utility here is Gefitinib.

Another possible therapy is TNF- α (tumor necrosis factor-alpha), a cytokine involved 20 in systemic inflammation and a member of a group of cytokines that stimulate the acute phase reaction. The primary role of TNF is in the regulation of immune cells. TNF is also able to induce apoptotic cell death, to induce inflammation, and to inhibit tumorigenesis and viral replication.

Agents that disrupt the synthesis and fidelity of nucleic acid precursors and subunits 25 also lead to DNA damage. As such a number of nucleic acid precursors have been developed. Particularly useful are agents that have undergone extensive testing and are readily available. As such, agents such as 5-fluorouracil (5-FU), are preferentially used by neoplastic tissue, making this agent particularly useful for targeting to neoplastic cells. Although quite toxic, 5-FU, is applicable in a wide range of carriers, including topical, however intravenous 30 administration with doses ranging from 3 to 15 mg/kg/day being commonly used.

Other factors that cause DNA damage and have been used extensively include what are commonly known as γ -rays, x-rays, and/or the directed delivery of radioisotopes to tumor cells. Other forms of DNA damaging factors are also contemplated such as microwaves and UV-

irradiation. It is most likely that all of these factors effect a broad range of damage DNA, on the precursors of DNA, the replication and repair of DNA, and the assembly and maintenance of chromosomes. Dosage ranges for x-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 weeks), to single doses of 2000 to 6000 roentgens. Dosage
5 ranges for radioisotopes vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells.

In addition, it also is contemplated that immunotherapy, hormone therapy, toxin therapy and surgery can be used.

The skilled artisan is directed to "Remington's Pharmaceutical Sciences" 15th Edition, Chapter 33, in particular pages 624-652. Some variation in dosage will necessarily occur
10 depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologics standards.

15 III. Examples

All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this disclosure have been described in terms of preferred
20 embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the disclosure. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or
25 similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the disclosure as defined by the appended claims.

EXAMPLE 1 – Materials and Methods

Ethics Statement. All clinical data and patient samples were collected following
30 approval by the Massachusetts General Hospital institutional review board and the Hospital of the University of Pennsylvania institutional review board. In all cases informed consent was obtained. All animal studies were conducted in accordance with the Guide for the Care and

Use of Laboratory Animals of the NIH. Mice were maintained according to the guidelines of the Wistar Institutional Animal Care and Use Committee (IACUC), and study designs were approved by the Wistar IACUC.

Cell Lines and Short-term Primary Cultures. All normal skin epidermal melanocytes, keratinocytes and human metastatic melanoma cell lines that were established at The Wistar Institute have been documented in world-wide-web at wistar.org/lab/meenhard-herlyn-dvm-dsc/page/resources. UACC-62 and UACC-903 cells were kind gifts from Dr. Marianne B. Powell (Stanford University, Stanford, CA 94305, USA). A375 cells were purchased from ATCC. LOX-IMVI cells were kindly provided by Dr. Lin Zhang (University of Pennsylvania, Philadelphia, PA 19104, USA). All resistant cell lines that acquired drug resistance to PLX4720 or GSK2118436 (hereafter referred to as “BR” cell lines) or the combination of PLX4720 and PD0325901 (hereafter referred to as “CR” cell lines) were established after continuous exposure to PLX4720 at 10 μ M, GSK2118436 at 1 μ M or the combination of PLX4720 at 10 μ M and PD0325901 at 1 μ M. 499 and JB2 cells were kind gifts from Dr. Andy Minn (University of Pennsylvania, Philadelphia, PA 19104, USA). Fine needle aspiration (FNA) tumor samples derived from melanoma patients were directly transplanted and grown in mice. Tumors were harvested, fragmented and re-transplanted in mice to establish melanoma patient-derived xenografts (PDX). Short-term primary cultures established from resistant PDXs (hereafter referred to as “RPDX” cell lines) were maintained in the presence of PLX4720 at 1 μ M. Human serous ovarian cancer cell lines PEO1, PEO4, PEO1-CR, WO-24-2 were established and cultured as previously described (George *et al.*, 2017; Kim *et al.*, 2016). PEO1 and PEO4 were kind gifts from Dr. Andrew Godwin (University of Kansas, Lawrence, Kansas, USA). Specifically, PEO1-CR cells were generated by long-term treatment of PEO1 cells with Carboplatin at 3-15 μ M over 10 months (Hospira, Lake Forest, IL). The WO-24-2 primary ovarian culture was generated from a patient with high grade serous ovarian cancer (HGSOC) and the cells were cultured in OCMI-E media (Live Tumor Culture Core at Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami). Except WO-24-2, all cell lines were maintained in RPMI-1640 media (Mediatech, Inc.) supplemented with 10% fetal bovine serum (Tissue Culture Biologicals) and cultured in a 37° C humidified incubator supplied with 5% CO₂. All cell lines were authenticated by DNA fingerprinting.

Chemicals. The BRAF inhibitor PLX4720 was provided by Plexxikon Inc. The BRAF inhibitor GSK2118436 and the MEK inhibitor PD0325901 were purchased from Selleckchem. 6-thio-dG used for *in vitro* studies was purchased from Metkinen Chemistry Oy. 6-thio-dG used for *in vivo* studies was purchased from R I Chemical Inc (Orange, CA 92868, USA).

Melanoma Xenotransplantation and *In vivo* Studies. 100,000 melanoma cells were harvested from cell culture and re-suspended in culture medium and Matrigel at a 1:1 ratio. Cells were subcutaneously injected into mice, which were treated with indicated inhibitors when the tumor volume reached 100 mm³. Mice were sacrificed at the end time point and solid
5 tumors were collected. All animal experiments were performed in accordance with Wistar IACUC protocol 112330 in NOD.Dg-Prkdc scidIL2rg tm 1 Wjl/SzJ mice.

DNA Purification, Library Preparation, and Sequencing. DNA purification was done using the DNeasy Blood & Tissue Kit (Qiagen). Fine hundred ng of genomic DNA was sheared randomly into 200 bp fragments with the CovarisTM S200 UltraSonicator
10 (Covaris®). Sheared DNA was A-tailed and ligated with adaptor-embedded indexes using the NEBNext[®] UltraTM DNA Library Prep Kit for Illumina[®] (New England BioLabs, Inc.). DNA quality, fragment size, and concentration of library preps were measured using Agilent's DNA 1000 chips in conjunction with the 2100 Bioanalyzer (Agilent Technologies). Samples were equimolarly pooled prior to capture with a 2.2 Mbp SureSelect^{XT} Custom Target Enrichment
15 Kit (Agilent Technologies) targeting 108 genes previously implicated in melanomagenesis. Paired-end sequencing was performed on the HiSeqTM 2000 sequencing system (Illumina) at the Perelman School of Medicine Next-Generation Sequencing Core Facility.

Mutational Analysis. Short-sequenced reads were aligned to the hg19 human
20 reference genome using the Burrows-Wheeler Alignment (BWA) tool. Duplicate reads were removed, as well as reads that map to more than one location, off-target reads, and variants annotated with the incorrect transcript. The Genome Analysis Toolkit (GATK) was used for data quality assurance as well as for Single Nucleotide Variant (SNV) and small insertion and deletion (indel) calling. After downsampling by GATK, a mean target coverage of 197X was
25 achieved. Variants were annotated with wANNOVAR.

Copy Number Variation Prediction. Prediction of copy number variation from sequencing data was done using CODEX. This algorithm normalizes the data using a Poisson latent factor model that removes biases due to GC content, exon capture, amplification efficiency, and latent systemic artifacts. Six latent factors were used for the normalization of
30 the dataset in this study. Segmentation was restricted to exons only for all genes. Only homozygous loss and high amplification calls are reported. Log₂ ratio thresholds used for high amplification and homozygous loss were 1.33 (copy number five) and -1.2, respectively. Visual confirmation of CNV calls was done in Nexus 7.5 (BioDiscovery, Inc.) software.

RNA Purification, Library Preparation, and Sequencing. RNA purification was done using the AllPrep DNA/RNA Mini Kit (Qiagen) for 31 tumor biopsy specimens. The first batch of 17 RNA samples were ribo-zero treated and then subject to library preparation using Epicentre's ScriptSeq Complete Gold kit. Quality check was done on the Bioanalyzer using the High Sensitivity DNA kit and quantification was carried out using KAPA Quantification kit. Samples were sequenced on Illumina's NextSeq500 with the 2X75 bp high output in the Genomics Core Facility at The Wistar Institute. The second batch of 14 RNA samples purified from tumor biopsy specimens along and the third batch of 12 RNA samples purified from A375 and LOX-IMVI BR cells were sequenced at Broad Institute to achieve the high coverage of 50M pairs. Briefly, the Tru-Seq Non-Strand Specific RNA Sequencing which includes plating, poly-A selection and non-strand specific cDNA synthesis, library preparation, sequencing, and sample identification QC check (when Sample Qualification of a matching DNA sample is chosen).

FACS Analysis of Apoptosis and Cell Death. Adherent cells were harvested with 0.05% Trypsin-EDTA, pooled with floating cells and then washed once with 1X DPBS. Cells were then pelleted and stained with PSVue® 643 at 0.5 μ M and Propidium iodide at 50 ug/ml diluted in TES buffer for 5 min in the dark. Cells were then immediately subjected to FACS analysis using a BD LSR II flow cytometer and at least 5,000 cells per sample were acquired.

Assessment of Cell Clonogenicity. Cells were seeded into 12-well tissue culture plates at a density of 500 cells/well as biological triplicates in drug-free medium. Medium was refreshed every 3 or 4 days for 14 days. Colonies were then stained overnight with methanol containing 0.05% crystal violet. After extensive washing with distilled H₂O, cells were air-dried and subjected to image acquisition using a Nikon D200 DSLR camera.

Gene Expression Microarray Data and RNA-seq Data from CCLE Melanoma Cell Lines and TCGA Melanoma Patients. Normalized CCLE gene expression microarray data were directly downloaded from Broad CCLE (<http://www.broadinstitute.org/ccle>). Normalized RNA-seq data of TCGA melanoma patients were downloaded from TCGA Data Portal (<http://tcga-data.nci.nih.gov/tcga/>). Single sample gene set enrichment analysis (ssGSEA) was performed in each data set to calculate an enrichment score of each gene set.

Gene Expression Microarray and RNA-seq Data from PDX and Relapsed Melanoma Patients. Gene expression microarray data and RNA-sequencing data of paired pre- and post-treatment tumor biopsies derived from melanoma patients were downloaded from GEO under accession number GSE50509, GSE50535, GSE61992 and GSE65185; patient RNA-seq data from the Tirosh I *et al.* data set were downloaded directly from

//science.sciencemag.org/content/352/6282/189.long (Tirosh *et al.*, 2016); RNA-seq data for patients treated with ipilimumab were deposited at The cBioPortal under the study name Metastatic Melanoma (MSKCC Cell, 2015). Data were normalized, background-corrected and summarized using the R package “lumi”.

5 **Analysis of Gene Expression Microarray Data and Reverse Phase Protein Array (RPPA) Data.** The raw data of gene expression microarrays generated from Illumina Chips were normalized, background-corrected and summarized using the R package “lumi”. Probes below background level (detection P-value <0.01) were excluded and differential expression was identified with Bayes-adjusted variance analysis using the Bioconductor Limma package.
10 To reduce false positives, the unexpressed probes were removed. The R package “limma” was employed for gene differential expression analysis, followed by multiple test correction by the Benjamini and Hochberg procedure. Genes with adjusted p values < 0.05 and fold change > 2 were claimed as significantly differentially expressed and were subjected to the hypergeometric test for gene set enrichment analysis (GSEA). The inventors also conducted GSEA as
15 previously reported. For GSEA, they analyzed gene sets obtained from the Molecular Signatures Database (world-wide-web at broadinstitute.org/gsea/msigdb/). The same differential expression analysis method was applied to RPPA data.

Kaplan-Meier Survival Analysis of TCGA Melanoma Patient Data. The inventors clustered TCGA melanoma patient RNA-seq data into 2 groups using Cox regression analysis
20 based on expression of two telomere transcriptional gene signatures. They then performed a log-rank test to test the survival rate difference between these subgroups.

Western Blotting and Antibodies. Cells were washed with ice-cold PBS containing 100 μ M Na_3VO_4 and scraped off culture dishes. After centrifugation, cell pellets were lysed in buffer containing 10 mM Tris-HCl, pH 7.8, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 1
25 mM Na_3VO_4 and protease inhibitors (Roche complete protease inhibitor tablets). Lysates were cleared by micro-centrifugation and protein concentrations were determined with Protein Assay Dye Reagent Concentrate (Bio-Rad). For western blots, 20 μ g of each lysate were run on 8% SDS-PAGE gels and transferred onto nitrocellulose membranes using a dye fast Trans-Blot^R TurboTM transfer system (Bio-Rad). Blots were blocked in SEA BLOCK Blocking Buffer
30 (Thermo Scientific) diluted with 1X TBS at 1:1 ratio at room temperature for 1 h, incubated overnight at 1:1000 dilutions with primary antibodies (anti-AXL: Bethyl Laboratories; anti- β -actin: Sigma; all other antibodies were purchased from Cell Signaling Technologies) at 4°C, stained with secondary antibodies conjugated to IRDye[®] Infrared Dyes (LI-COR Biosciences) and then visualized using an Odyssey flatbed scanner (LI-COR Biosciences).

Telomere dysfunction Induced Foci (TIF) Assay. The TIF assay is based on the co-localization detection of DNA damage by an antibody against gamma-H2AX, and telomeres using FITC-conjugated telomere sequence (TTAGGG)₃-specific peptide nucleic acid (PNA) probe. Briefly, LOX-IMVI-BR cells were seeded to 6-well plate (50,000 cells/well). After cells adhered to the surface (next day), 6-thio-dG was added with fresh medium. Cells were treated with or without 6-thio-dG at 5 μ M every two days for 4 days. Then cells were harvested and cell numbers were counted. 100,000 cells were re-plated in 4-well chamber slides. After cells adhered to the chamber slide (next day), cells were rinsed twice with 1xPBS and fixed in 4% paraformaldehyde in PBS for 10 minutes. Cells were washed twice with PBS and permeabilized in 0.5% Triton X-100 in PBS for 10 minutes. Following permeabilization, cells were washed three times with PBS. Cells were blocked with 0.2% Fish gelatin and 0.5% BSA in PBS for 30 minutes. Gamma-H₂AX (mouse) (Millipore, Billerica, MA) was diluted 1:1000 in blocking solution and incubated with cells for 2 hrs. Following three washes with PBST (1x PBS in 0.1% Triton) and 3 washes with PBS, cells were incubated with Alexaflour 568 conjugated goat anti mouse (1:500) (Invitrogen, Grand Island, NY) for 40 minutes, then were washed five times with 0.1% PBST. Cells were fixed in 4% paraformaldehyde in PBS for 20 minutes at room temperature. The slides were sequentially dehydrated with 70%, 90%, 100% ethanol. Following dehydration, denaturation was conducted with hybridization buffer containing FITC-conjugated telomere sequence (TTAGGG)₃-specific peptide nucleic acid (PNA) probe (PNA Bio, Thousand Oaks, CA), 70 % formamide, 30% 2xSSC, 10% (w/v) MgCl₂.6H₂O (Fisher Sci), 0.25% (w/v) blocking reagent for nucleic acid hybridization and detection (Roche) for 7 minutes at 80°C on heat block, followed by overnight incubation at room temperature. Slides were washed sequentially with 70% formamide (Ambion, Life Technologies, Grand Island, NY) / 0.6 x SSC (Invitrogen) (2 x 1 hr), 2 x SSC (1 x 15 minutes), PBS (1 x 5 minutes) and sequentially dehydrated with 70%, 90%, 100% ethanol, then mounted with Vectashield mounting medium with DAPI (Vector Laboratories, Burlingame, CA). Images were captured with Deltavision wide-field microscope using the 60X objective, then deconvoluted using Autoquant X3. Gamma-H2AX and TIFs were quantified using Imaris software.

SA- β -gal Staining. Cells were fixed with DPBS containing 2% formaldehyde (Sigma) and 0.2% glutaraldehyde (Sigma) for 30 minutes. Fixed cells were then incubated at 37°C (no CO₂) with fresh SA- β -gal staining solution overnight. Images were acquired with Nikon TE2000 Inverted Microscope.

Telomere length quantification. Telomere length was measured by the ratio of the telomeric DNA and a single copy gene, 36B4. The forward and reverse primers used for amplifying telomeric DNA were tel1b and tel2b. The quantification of telomeric DNA and 36B4 was determined by quantitative real time PCR on Applied Biosystems 7500 Fast Real-
5 Time PCR System. The reaction mixtures (20 μ L final volume) contained 10 μ L Fast SYBR® Green Master Mix, 500nM each primer and 10ng genomic DNA. The reaction conditions were 95°C for 20s, followed by 40 cycles of 95°C for 3s and 60°C for 30s. The telomere length was analyzed by $2^{-\Delta\Delta C_t}$ method.

Patients' cDNA Samples and Quantitative Real-Time PCR. Total RNA was purified
10 from patients' tumor biopsies according to the manufacture's instruction (RNeasy Mini Kit, Qiagen). One μ g total mRNA was reverse transcribed using a Maxima First Strand cDNA Synthesis Kit for qRT-PCR (Thermo Fisher). Fast SYBR® Green Master Mix (Life Technologies) was used with cDNA template and primers to evaluate the expression of *TERT* and GAPDH. Primers used were purchased from Integrated DNA Technologies.
15 Amplifications were performed using an Applied Biosystems® 7500 Real-Time PCR System (Life Technologies). All experiments were performed in triplicate. Expression ratios of controls were normalized to 1. Please see Extended Experimental Procedures for the list of PCR primer sequences.

Statistics. Unless otherwise indicated, data in the figures were presented as mean $\pm$
20 SEM for 3 biological or technical replicates. Significant differences between experimental conditions were determined using the two-tailed unpaired t test. For survival data, Kaplan–Meier survival curves were generated and their differences were examined with Log-rank test. For tumor growth data, mixed effect models were used to determine the differences between treatment groups in tumor volume change at the end of experiment. A two-sided *p* value of less
25 than 0.05 was considered statistically significant. *: *p* <0.05; **: *p* <0.005; ***: *p* <0.0005.

EXAMPLE 2 - Results

Treatment of a Variety of Cancer Cell Lines with Telomerase-directed 6-thio-dG Impairs Cell Viability. It has previously been shown that 6-thio-dG inhibited cell viability of
30 the colon cancer cell line, HCT-116 and the non–small cell lung cancer cell line, A549 (Mender *et al.*, 2015). To further confirm the inhibitory effect of 6-thio-dG, a panel of 12 cancer cell lines of 9 different histological origins was treated with 6-thio-dG for 9-12 days. As the control for 6-thio-dG, a known telomerase inhibitor, BIBR 1532, was also included. In most cases,

these cancer cell lines were sensitive to 6-thio-dG administered at a dose of 2.5 μ M and higher (**FIG. 1A**). The anti-proliferative activity of BIBR 1532 was also observed in a subset of 12 cancer cell lines that were administered at a dose of 25 μ M (**FIG. 1A**).

The *TERT* promoter is often mutated in human cancers including melanoma. Massively parallel sequencing (MPS) of 108 genes that are implicated in melanomagenesis was conducted (**Table 1**). Collectively, various *TERT* promoter mutations (Chr5:1295161 T>G; Chr5:1295228 G>A; Chr5:1295228-1295229 GG>AA; Chr5:1295242 G>A; Chr5:1295242-1295243 GG>AA; and Chr5:1295250 G>A) were identified in 73.2% of 97 melanoma cell lines, 67.4% of 172 melanoma therapy-naïve patient-derived xenografts (PDX), and 79.4% of 34 melanoma PDX that acquired resistance to MAPKi (**FIG. 2; Tables 2-4**). These observations are in line with sequencing data from the Cancer Genome Atlas (TCGA) showing that 64.3% of 115 cases of skin cutaneous melanoma (SKCM) harbor mutations in the *TERT* promoter (**FIG. 2; Table 5**). The frequency of *TERT* promoter mutations in melanoma cell lines, melanoma PDXs and TCGA SKCM is very similar to that of *BRAF*^{V600} mutations (**FIG. 2**). Not surprisingly, *TERT* was the second most frequently mutated gene after *BRAF* in the MAPKi-resistant PDX data set. Thus, the results confirm and further highlight the prevalence of *TERT* promoter mutations in both therapy-naïve and therapy-resistant melanomas.

Table 1. The list of 108 genes included in massively parallel sequencing.

Full Gene	Exonic Regions		
APC	ABL1	GRM3	RAC1
ARID1A	AKT1	HRAS	RAC2
ARID2	AKT3	IDH1	RET
ATM	ALK	IDH2	RHOT1
BAP1	ARID1B	JAK3	SETD2
BRAF	CASP8	KDR	SMARCA4
BRCA1	CCND1	KIT	SMO
BRCA2	CCND2	KRAS	SNX31
CDC42	CDK4	MAP2K1	SOX10
CDKN2A	CDK6	MAP2K2	SRC
CDKN2B	CTNNB1	MAP3K5	STK19
EIF2AK3	CXCR4	MAP3K9	STK24
EZH1	DCC	MDM2	TACC1
EZH2	DDX3X	MDM4	TRRAP
MLH1	DYNC1I1	MET	VAV3
NF1	EGFR	MITF	
NF2	ERBB2	MMP8	
NTRK1	ERBB3	MYC	
PIK3CA	ERBB4	NOTCH1	
PRDM1	FBXO4	NOTCH2	
PRDM2	FBXW7	NRAS	
PTEN	FGF3	PDGFRA	
RB1	FGF4	PDGFRB	
ROS1	FGFR2	PIK3CB	
SMAD4	FGFR3	PPP6C	
SMARCB1	FGFR4	PRC1	
STK11	FLT3	PREX1	
TERT	GNA11	PREX2	
TP53	GNAQ	PTCH1	
VHL	GNAS	PTPRD	
WT1	GRIN2A	PTPRK	

Table 2. TERT promoter mutations in Wistar's melanoma cell lines.

Sample	Sample Type	Sub-type	BRAF	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
Skmel28p93	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT chr5:1295161 T>G	VUS		
ND238p5	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228 G>A	Deleterious		
WM1716p10	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228 G>A	Deleterious		
WM1799p11	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228 G>A	Deleterious		
WM3248p35	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228 G>A	Deleterious		
WM3301p2+	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228 G>A	Deleterious		
WM793p61	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228 G>A	Deleterious		
WM858p39	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228 G>A	Deleterious		
WM873-1	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228 G>A	Deleterious		
WM983Cp43	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228 G>A	Deleterious		

Sample	Sample Type	Sub-type	BRAF	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM3172 p17	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295242 G>A	VUS		
WM3704 p24	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295250 G>A	Deleterious		
WM88p4 9	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295250 G>A	Deleterious		
WM989	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295250 G>A	Deleterious		
451Lu-C2-MR	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295250 G>A	Deleterious		
WM1232 p94	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295250 G>A	Deleterious		
WM164p 127	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295250 G>A	Deleterious		
WM853-2p36	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295242-1295243 GG>AA	Deleterious		
WM983 B-BR	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228 G>A	Deleterious		
WM1727 A	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228 G>A	Deleterious		

Sample	Sample Type	Sub-type	BRAF	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM3482 p31	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228 G>A	Deleterious		
WM1158 p14+	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295250 G>A	Deleterious		
WM2090 p15	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295250 G>A	Deleterious		
WM1026 p22	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228 G>A	Deleterious		
WM3533 p13	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228 G>A	Deleterious		
WM373p 31	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228 G>A	Deleterious		
WM75p1 7	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228 G>A	Deleterious		
WM983 Ap5	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228 G>A	Deleterious		
WM9p68	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228 G>A	Deleterious		
M331p16	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228 G>A	Deleterious	TERT Chr5:1295250 G>A	Deleterious

Sample	Sample Type	Sub-type	BRAF	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM1819 p4	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295228-1295229 GG>AA	Deleterious		
WM2044 p12	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295242-1295243 GG>AA	Deleterious		
WM1985 p4	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295250 G>A	Deleterious		
WM902 Bp11	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295250 G>A	Deleterious		
LH6215p 7	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295250 G>A	Deleterious	TERT chr5:1295172-1295173 CC>TT	VUS
WM3630 p5	Cell Line	BRAF Hotspot-Mutant	BRAF V600E	TERT Chr5:1295250 G>A	Deleterious	TERT chr5:1295205 G>A	VUS
WM3282 p20	Cell Line	BRAF Hotspot-Mutant	BRAF V600K	TERT Chr5:1295250 G>A	Deleterious	TERT chr5:1295205 G>A	VUS
WM115	Cell Line	BRAF Hotspot-Mutant	Other BRAF Hotspot	TERT Chr5:1295250 G>A	Deleterious		
WM1341 Dp37	Cell Line	BRAF Hotspot-Mutant	Other BRAF Hotspot	TERT Chr5:1295250 G>A	Deleterious		
WM239 Ap41	Cell Line	BRAF Hotspot-Mutant	Other BRAF Hotspot	TERT Chr5:1295250 G>A	Deleterious		

Sample	Sample Type	Sub-type	BRAF	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM266-4	Cell Line	BRAF Hotspot-Mutant	Other BRAF Hotspot	TERT Chr5:1295250 G>A	Deleterious		
WM165-1p212	Cell Line	BRAF Hotspot-Mutant	Other BRAF Hotspot	TERT Chr5:1295250 G>A	Deleterious		
WM1361 Ap40	Cell Line	RAS Hotspot-Mutant		TERT Chr5:1295228 G>A	Deleterious		
WM3506 p33	Cell Line	RAS Hotspot-Mutant		TERT Chr5:1295228 G>A	Deleterious		
WM3619 p10	Cell Line	RAS Hotspot-Mutant		TERT Chr5:1295228 G>A	Deleterious		
WM2032	Cell Line	RAS Hotspot-Mutant		TERT Chr5:1295228 G>A	Deleterious	TERT Chr5:1295242-1295243 GG>AA	Deleterious
WM3451	Cell Line	RAS Hotspot-Mutant		TERT Chr5:1295242-1295243 GG>AA	Deleterious		
WM3268 p13	Cell Line	RAS Hotspot-Mutant		TERT Chr5:1295250 G>A	Deleterious		
WM3406 p2+	Cell Line	RAS Hotspot-Mutant		TERT Chr5:1295250 G>A	Deleterious		
WM3702	Cell Line	RAS Hotspot-Mutant		TERT Chr5:1295250 G>A	Deleterious		

Sample	Sample Type	Sub-type	BRAF	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM3758 p19	Cell Line	RAS Hotspot-Mutant		TERT Chr5:1295250 G>A	Deleterious		
WM3854 p12	Cell Line	RAS Hotspot-Mutant		TERT Chr5:1295250 G>A	Deleterious		
WM1366 p60	Cell Line	RAS Hotspot-Mutant		TERT Chr5:1295250 G>A	Deleterious		
WM1960 p10	Cell Line	RAS Hotspot-Mutant		TERT Chr5:1295250 G>A	Deleterious		
WM2013 p36	Cell Line	RAS Hotspot-Mutant		TERT Chr5:1295250 G>A	Deleterious		
WM3060	Cell Line	RAS Hotspot-Mutant		TERT Chr5:1295250 G>A	Deleterious		
WM3623 p15	Cell Line	RAS Hotspot-Mutant		TERT Chr5:1295250 G>A	Deleterious	TERT chr5:1295230-1295231 GG>AA	VUS
M230p6	Cell Line	RAS Hotspot-Mutant	BRAF V600K	TERT Chr5:1295228-1295229 GG>AA	Deleterious	TERT chr5:1295230 G>A	VUS
WM209p 11	Cell Line	RAS Hotspot-Mutant		TERT Chr5:1295228 G>A	Deleterious		
WM1791 Cp14+	Cell Line	RAS Hotspot-Mutant		TERT Chr5:1295250 G>A	Deleterious		
WM3211	Cell Line	KIT-Mutant		TERT Chr5:1295250 G>A	Deleterious		

Sample	Sample Type	Sub-type	BRAF	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM3912 p9	Cell Line	NF1-Mutant	Non-BRAF Hotspot	TERT Chr5:1295228 G>A	Deleterious		
WM3622 p18	Cell Line	NF1-Mutant		TERT Chr5:1295250 G>A	Deleterious	TERT Chr5:1295253 G>A	VUS
WM1963 p21	Cell Line	NF1-Mutant	Non-BRAF Hotspot	TERT Chr5:1295250 G>A	Deleterious		
TH202p14	Cell Line	Wildtype		TERT Chr5:1295228 G>A	Deleterious		
WM3311 p6+	Cell Line	Wildtype		TERT Chr5:1295228 G>A	Deleterious	TERT chr5:1295238 C>T	VUS
WM3438 p6	Cell Line	Wildtype		TERT Chr5:1295250 G>A	Deleterious		
WM3918 p82	Cell Line	Wildtype		TERT Chr5:1295250 G>A	Deleterious		
WM3246 p17	Cell Line	Wildtype		TERT Chr5:1295228 G>A	Deleterious	TERT Chr5:1295253-1295254 GG>AA	VUS
WM3928 -2p3	Cell Line	Wildtype		TERT Chr5:1295228 G>A	Deleterious		
WM3743 p24	Cell Line	Wildtype		TERT Chr5:1295250 G>A	Deleterious		

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
CS190MP2	PDX	BRAF Hotspot-Mutant	BRAF V600K			TERT Chr5:1295228 G>A	Deleterious		
RC6041MP1Mouse eNum1365	PDX	RAS Hotspot-Mutant			NRAS 12/3	TERT Chr5:1295228 G>A	Deleterious		
RR214MP1Mouse Num5171	PDX	RAS Hotspot-Mutant			NRAS Codon 61	TERT Chr5:1295228 G>A	Deleterious		
WM3703MP1Mouse useNum8244	PDX	RAS Hotspot-Mutant			NRAS Codon 61	TERT Chr5:1295228 G>A	Deleterious		
WM3903-1MP5MouseNum4045	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295242 G>A	VUS		
WM3903-1MP6MouseNum6576	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295228 G>A	Deleterious		
WM3908MP3MouseNum1563RECUT	PDX	BRAF Hotspot-Mutant	BRAF V600K			TERT Chr5:1295250 G>A	Deleterious		
WM3908MP4PLXMouseNum6433RECUT	PDX	BRAF Hotspot-Mutant	BRAF V600K			TERT Chr5:1295250 G>A	Deleterious		
WM3909PLX2M P7	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM3915-2MP1MouseNum1337	PDX	RAS Hotspot-Mutant			NRAS Codon 61	TERT Chr5:1295228 G>A	Deleterious		
WM3921MP1	PDX	Wildtype				TERT Chr5:1295228 G>A	Deleterious		
WM3924MP4Mo useNum3855	PDX	RAS Hotspot-Mutant			NRAS Codon 61	TERT Chr5:1295228 G>A	Deleterious		
WM3927MP2Mo useNum3888	PDX	BRAF Hotspot-Mutant	BRAF V600K			TERT Chr5:1295228 G>A	Deleterious		
WM3931MP2Mo useNum3228	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		
WM3933MP1Mo useNum	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295242 G>A	VUS		
WM3937MP1	PDX	RAS Hotspot-Mutant			NRAS 12/3	TERT Chr5:1295250 G>A	Deleterious		
WM3939-2CPLXMP6MouseNum5900	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295242 G>A	VUS		
WM3941-1MP3MouseNum8890	PDX	BRAF Hotspot-Mutant	Other BRAF Hotspot			TERT Chr5:1295250 G>A	Deleterious		

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM3942CPLXM P3MouseNum888 5	PDX	BRAF Hotspot- Mutant	BRAF V600E			TERT Chr5:1295228 G>A	Deleterious		
WM3960MP4Mo useNum3960	PDX	BRAF Hotspot- Mutant	BRAF V600E			TERT Chr5:1295228 G>A	Deleterious		
WM3973MP3Mo useNum3470	PDX	BRAF Hotspot- Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		
WM3973MP4Mo useNum7144	PDX	BRAF Hotspot- Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		
WM3973PLXMP 5MouseNum7627	PDX	BRAF Hotspot- Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		
WM3983PLXMP 7MouseNum8003	PDX	RAS Hotspot- Mutant	BRAF V600K		NRAS Codon 61	TERT Chr5:1295250 G>A	Deleterious		
WM3991MPIMo useNum4044	PDX	Wildtype				TERT chr5:1295161 T>G	VUS		
WM3994- 3MP2MouseNum 127	PDX	BRAF Hotspot- Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		
WM3994MPIMo useNum366IREC UT	PDX	BRAF Hotspot- Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM3997MP3Mo useNum8120	PDX	BRAF Hotspot- Mutant	BRAF V600K			TERT Chr5:1295228 G>A	Deleterious		
WM4003MP1Mo useNum8866	PDX	Wildtype				TERT Chr5:1295228 G>A	Deleterious		
WM4008MP2Mo useNum4345	PDX	BRAF Hotspot- Mutant	BRAF V600K			TERT Chr5:1295250 G>A	Deleterious		
WM4008MP4743 3	PDX	BRAF Hotspot- Mutant	BRAF V600K			TERT Chr5:1295250 G>A	Deleterious		
WM4018- 7MP1MouseNum 0332	PDX	BRAF Hotspot- Mutant	BRAF V600K			TERT Chr5:1295242 G>A	VUS		
WM4023MP1Mo useNum2770	PDX	RAS Hotspot- Mutant			NRAS Codon 61	TERT Chr5:1295250 G>A	Deleterious		
WM4035MP1Mo useNum2736	PDX	BRAF Hotspot- Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		
WM4037MP1Mo useNum3896	PDX	BRAF Hotspot- Mutant	BRAF V600E			TERT Chr5:1295228 G>A	Deleterious		
WM4042MP1Mo useNum4897	PDX	RAS Hotspot- Mutant			NRAS Codon 61	TERT Chr5:1295228 G>A	Deleterious		

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM4053-2MP1MouseNum5272	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295228 G>A	Deleterious		
WM4055MP1MouseNum5191	PDX	BRAF Hotspot-Mutant	BRAF V600K			TERT Chr5:1295228 G>A	Deleterious		
WM4070-2MP4MouseNum6758	PDX	BRAF Hotspot-Mutant	BRAF V600K			TERT Chr5:1295228 G>A	Deleterious		
WM4071-1MP2MouseNum6673	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		
WM4071-2MP2717	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		
WM4073MP1MouseNum8858	PDX	NF1-Mutant				TERT Chr5:1295228 G>A	Deleterious		
WM4089MP1MouseNum6553	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295228 G>A	Deleterious		
WM4115MP2MouseNum8865	PDX	NF1-Mutant				TERT Chr5:1295250 G>A	Deleterious		
WM4150MP1MouseNum8407	PDX	BRAF Hotspot-Mutant	BRAF V600K			TERT Chr5:1295250 G>A	Deleterious		

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM4205-1MP1MouseNum6786	PDX	BRAF Hotspot-Mutant	Other BRAF Hotspot			TERT Chr5:1295250 G>A	Deleterious		
WM4205-2PLXMP3MouseNum8835	PDX	BRAF Hotspot-Mutant	Other BRAF Hotspot			TERT Chr5:1295250 G>A	Deleterious		
WM4205-3MP2MouseNum7681	PDX	BRAF Hotspot-Mutant	Other BRAF Hotspot			TERT Chr5:1295250 G>A	Deleterious		
WM4206MP1Mo useNum6761	PDX	BRAF Hotspot-Mutant	BRAF V600K			TERT Chr5:1295250 G>A	Deleterious		
WM4208MP1Mo useNum6778	PDX	RAS Hotspot-Mutant			NRAS Codon 61	TERT Chr5:1295228 G>A	Deleterious		
WM4210MP1Mo useNum7463	PDX	NF1-Mutant				TERT Chr5:1295228-1295229 GG>AA	Deleterious		
WM4215MP1Mo useNum6780	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295228 G>A	Deleterious		
WM4223MP1Mo useNum7296	PDX	KIT-Mutant	Non-BRAF Hotspot			TERT Chr5:1295228 G>A	Deleterious		
WM4224MP1Mo useNum7476	PDX	RAS Hotspot-Mutant			NRAS Codon 61	TERT Chr5:1295250 G>A	Deleterious		

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM4225MP1Mo useNum7427	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295228 G>A	Deleterious		
WM4231-2MP1MouseNum7874	PDX	RAS Hotspot-Mutant	Non-BRAF Hotspot		NRAS Codon 61	TERT Chr5:1295250 G>A	Deleterious		
WM4235MP1Mo useNum7858	PDX	RAS Hotspot-Mutant			NRAS Codon 61	TERT Chr5:1295250 G>A	Deleterious		
WM4237-2MP2MouseNum0302	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		
WM4237MP1Mo useNum8174	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		
WM4242MP1Mo useNum7647	PDX	Wildtype				TERT Chr5:1295228 G>A	Deleterious		
WM4243MP1Mo useNum7649	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295228 G>A	Deleterious		
WM4248MP1Mo useNum8088	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		
WM4250MP1Mo useNum8072	PDX	Wildtype				TERT Chr5:1295228 G>A	Deleterious		

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM4251MPIMo useNum8074	PDX	RAS Hotspot-Mutant			NRAS Codon 61	TERT Chr5:1295228 G>A	Deleterious		
WM4254MPIMo useNum8794	PDX	Wildtype				TERT Chr5:1295228 G>A	Deleterious		
WM4255MPIMo useNum8584	PDX	BRAF Hotspot-Mutant	BRAF V600K			TERT Chr5:1295228 G>A	Deleterious		
WM4257MPIMo useNum8616	PDX	NF1-Mutant			NRAS Codon 61	TERT Chr5:1295228 G>A	Deleterious		
WM4260MPIMo useNum8641	PDX	KIT-Mutant				TERT Chr5:1295250 G>A	Deleterious		
WM4262CPLXM P2MouseNum8592	PDX	RAS Hotspot-Mutant	BRAF V600E		NRAS 12/3	TERT Chr5:1295228 G>A	Deleterious		
WM4264-2MPIMouseNum9997	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295228 G>A	Deleterious		
WM4266MPIMo useNum9157	PDX	Wildtype				TERT Chr5:1295250 G>A	Deleterious		
WM4274MPIMo useNum8588	PDX	Wildtype				TERT Chr5:1295228 G>A	Deleterious		

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM4276MP1MouseNum8599	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295228 G>A	Deleterious		
WM4280PLXMP1MouseNum9005	PDX	RAS Hotspot-Mutant	BRAF V600K		NRAS 12/3	TERT Chr5:1295228 G>A	Deleterious		
WM4285MP1MouseNum9571	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		
WM4286-1MP1MouseNum9741	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		
WM4292MP1MouseNum9914	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		
WM4295-2MP1MouseNum0041	PDX	Wildtype				TERT Chr5:1295250 G>A	Deleterious		
WM4295-3MP1MouseNum0045	PDX	Wildtype				TERT Chr5:1295250 G>A	Deleterious		
WM4295MP1MouseNum9772	PDX	Wildtype				TERT Chr5:1295250 G>A	Deleterious		
WM4299-1MP1	PDX	RAS Hotspot-Mutant			NRAS Codon 61	TERT Chr5:1295228 G>A	Deleterious		

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM4299-2MP1MouseNum9947	PDX	RAS Hotspot-Mutant			NRAS Codon 61	TERT Chr5:1295228 G>A	Deleterious		
WM4299-3MP1MouseNum9988	PDX	RAS Hotspot-Mutant			NRAS Codon 61	TERT Chr5:1295228 G>A	Deleterious		
WM4299-4MP1MouseNum9994	PDX	RAS Hotspot-Mutant			NRAS Codon 61	TERT Chr5:1295228 G>A	Deleterious		
WM4319MPI1MouseNum0381	PDX	RAS Hotspot-Mutant			NRAS Codon 61	TERT Chr5:1295228 G>A	Deleterious		
WM4324MPI1MouseNum0753	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		
WM4330MPI1MouseNum0831	PDX	Wildtype	Non-BRAF Hotspot			TERT Chr5:1295228 G>A	Deleterious		
WTH202MP4MouseNum8340	PDX	Wildtype				TERT Chr5:1295228 G>A	Deleterious		
WM3926MP2MouseNum6234	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious	TERT chr5:1295205 G>A	VUS
WM3926PLXMP4MouseNum8063	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious	TERT chr5:1295205 G>A	VUS

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM3977MP2Mo useNum3383	PDX	BRAF Hotspot-Mutant	BRAF V600K			TERT Chr5:1295228 G>A	Deleterious	TERT chr5:1295205 G>A	VUS
WM4053-1MP1MouseNum 5202	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295228 G>A	Deleterious	TERT Chr5:1295490 C>A	VUS
WM4068MPI1Mo useNum6517	PDX	RAS Hotspot-Mutant	Non-BRAF Hotspot	Codon 12/13		TERT Chr5:1295228-1295229 GG>AA	Deleterious	TERT chr5:1295230 G>A	VUS
WM4099MPI1Mo useNum6233	PDX	NF1-Mutant				TERT Chr5:1295242-1295243 GG>AA	Deleterious	TERT chr5:1295200 G>A	VUS
WM4214MPI1Mo useNum6835	PDX	RAS Hotspot-Mutant			NRAS Codon 61	TERT Chr5:1295228 G>A	Deleterious	TERT chr5:1295230 G>A	VUS
WM4281MPI1Mo useNum9139	PDX	NF1-Mutant				TERT Chr5:1295228 G>A	Deleterious	TERT chr5:1295230 G>A	VUS
WM4351-2MP1MouseNum 1154	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295228 G>A	Deleterious	TERT chr5:1295230 G>A	VUS
WM3902MP5Mo useNum6556	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295228 G>A	Deleterious	TERT Chr5:1295250 G>A	Deleterious
WM3934MPI1Mo useNum1757	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious	TERT Chr5:1295250 G>A	Deleterious

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM3907-1MP3MouseNum3414	PDX	BRAF Hotspot-Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM3909MP6Mo useNum6870	PDX	BRAF Hotspot-Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM3940MP1Mo useNum1716	PDX	BRAF Hotspot-Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM3940MP4Mo useNum4860	PDX	BRAF Hotspot-Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM3960CPLXM P4MouseNum5838	PDX	BRAF Hotspot-Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM3963-2MP3MouseNum8176	PDX	BRAF Hotspot-Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM3965-2MP1MouseNum3054	PDX	BRAF Hotspot-Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM3971MP3Mo useNum3395	PDX	BRAF Hotspot-Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4002MP1Mo useNum5243	PDX	BRAF Hotspot-Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM4011MP2Mo useNum5833	PDX	BRAF Hotspot-Mutant	BRAF V600K			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4052MP2Mo useNum7685	PDX	BRAF Hotspot-Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4061MP2Mo useNum6593	PDX	BRAF Hotspot-Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4070-1MP2MouseNum6546	PDX	BRAF Hotspot-Mutant	BRAF V600K			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4096MPI1Mo useNum6666	PDX	BRAF Hotspot-Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4125MP3Mo useNum1330	PDX	BRAF Hotspot-Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4191MP2Mo useNum9869	PDX	BRAF Hotspot-Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4198MP3Mo useNum19821984	PDX	BRAF Hotspot-Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4200MPI1Mo useNum6669	PDX	BRAF Hotspot-Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM4249MP1Mo useNum8724	PDX	BRAF Hotspot-Mutant	BRAF V600E		Likely Deleterious Missense	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4298MP1Mo useNum9018	PDX	BRAF Hotspot-Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM3936-2MP1MouseNum 2975RECUT	PDX	RAS Hotspot-Mutant	BRAF V600E		NRAS Codon 61	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM3936-2MP5MouseNum 3646	PDX	RAS Hotspot-Mutant	BRAF V600E		NRAS Codon 61	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM3972MP2Mo useNum3241REC UT	PDX	RAS Hotspot-Mutant			NRAS Codon 61	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM3974MP3Mo useNum2726	PDX	RAS Hotspot-Mutant			NRAS Codon 61	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM3974MP4Mo useNum8186	PDX	RAS Hotspot-Mutant			NRAS 12/3	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4067MP1Mo useNum6254	PDX	RAS Hotspot-Mutant		Codon 12/13		No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4180MP1	PDX	RAS Hotspot-Mutant	BRAF V600E		NRAS Codon 61	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM4331MPIMo useNum0552	PDX	RAS Hotspot-Mutant			NRAS Codon 61	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4233MPIMo useNum7641	PDX	NF1-Mutant			NRAS Codon 61	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4175MP3Mo useNum9065	PDX	KIT-Mutant				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4279MPIMo useNum9791	PDX	KIT-Mutant				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
BM550MP2MouseNum7161	PDX	Wildtype				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4010MPIMo useNum4551	PDX	Wildtype				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4034MPIMo useNum4587	PDX	Wildtype				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4039-2MPIMouseNum5538	PDX	Wildtype				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4058MPIMo useNum5536	PDX	Wildtype				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM4087LMP1MouseNum6265	PDX	Wildtype				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4173MP1MouseNum8174	PDX	Wildtype				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4175MP4MouseNum8522	PDX	Wildtype				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4188MP3MouseNum9625	PDX	Wildtype				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4216MP1MouseNum7349	PDX	Wildtype				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4222MP1MouseNum7427	PDX	Wildtype				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4226MP1MouseNum7426	PDX	Wildtype				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4240MP1MouseNum8721	PDX	Wildtype				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4263MP1MouseNum8859	PDX	Wildtype				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM4307-2MP1MouseNum9655	PDX	Wildtype				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4309MP1MouseNum0161	PDX	Wildtype				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4323MP1MouseNum0757	PDX	Wildtype				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4341MP1MouseNum1040	PDX	Wildtype				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
PM171MP1MouseNum8860RECUT	PDX	BRAF Hotspot-Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM3901PLXMP3MouseNum6529	PDX	BRAF Hotspot-Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM3929MP5MouseNum5364	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		
WM3929MP6PLXMouseNum6566RECUT	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		
WM3935MP1MouseNum1752	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM3964MP1Mo useNum5198	PDX	RAS Hotspot- Mutant	Non- BRAF Hotspot	Codon 61		No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM3981MP1	PDX	BRAF Hotspot- Mutant	BRAF V600E			TERT Chr5:1295250 G>A	Deleterious		
WM3992MP2Mo useNum4501	PDX	RAS Hotspot- Mutant			NRAS Codon 61	TERT Chr5:1295228 G>A	Deleterious		
WM3993MP1Mo useNum5183	PDX	BRAF Hotspot- Mutant	BRAF V600E			TERT Chr5:1295228 G>A	Deleterious		
WM4007MP1Mo useNum8970	PDX	BRAF Hotspot- Mutant	BRAF V600E			No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4077MP3Mo useNum7109	PDX	NF1- Mutant	Non- BRAF Hotspot		NRAS 12/3	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4082MP1Mo useNum6215	PDX	NF1- Mutant				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4088MP1Mo useNum5845	PDX	BRAF Hotspot- Mutant	BRAF V600E			TERT Chr5:1295242 G>A	VUS		
WM4211MP1Mo useNum6779	PDX	BRAF Hotspot- Mutant	BRAF V600E			TERT Chr5:1295228 G>A	Deleterious		

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM4228MP1Mo useNum7653	PDX	BRAF Hotspot-Mutant	Other BRAF Hotspot			TERT Chr5:1295228 G>A	Deleterious	TERT Chr5:1295230 G>A	VUS
WM4239MP1Mo useNum8082	PDX	BRAF Hotspot-Mutant	BRAF V600K			TERT Chr5:1295250 G>A	Deleterious		
WM4247MP1Mo useNum8087	PDX	BRAF Hotspot-Mutant	BRAF V600K			TERT Chr5:1295250 G>A	Deleterious		
WM4265-1MP1MouseNum 8532	PDX	RAS Hotspot-Mutant			NRAS Codon 61	TERT Chr5:1295250 G>A	Deleterious	TERT chr5:1295205 G>A	VUS
WM4265-2MP1MouseNum 8534	PDX	RAS Hotspot-Mutant			NRAS Codon 61	TERT Chr5:1295250 G>A	Deleterious	TERT chr5:1295205 G>A	VUS
WM4267MP2Mo useNum8578	PDX	Wildtype				No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation	No TERT Promoter Mutation
WM4272MP1Mo useNum8251	PDX	RAS Hotspot-Mutant			NRAS Codon 61	TERT Chr5:1295250 G>A	Deleterious	TERT chr5:1295205 G>A	VUS
WM4273MP1Mo useNum8852	PDX	RAS Hotspot-Mutant			NRAS Codon 61	TERT Chr5:1295228 G>A	Deleterious		
WM4311MP1Mo useNum9937	PDX	BRAF Hotspot-Mutant	BRAF V600E			TERT Chr5:1295228 G>A	Deleterious		

Table 3. TERT promoter mutations in Wistar's treatment-naïve PDX									
Sample	Sample Type R-plot Code	sub-type	BRAF	KRAS	NRAS	TERT Promoter Mutation	TERT Promoter Mutation Call	Second TERT Promoter Mutation	Second TERT Promoter Mutation Call
WM4314MP1Mo useNum0008	PDX	NF1- Mutant				TERT Chr5:1295250 G>A	Deleterious		

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX						
Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM3901PLXMP3MouseN um6529	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM3901PLXMP3MouseN um6529	CDKN2A:NM_000077:exon2:c.197_219del:p.66_73del		Deleterious	CDKN 2A	frameshift deletion	het
WM3901PLXMP3MouseN um6529	FLT3:NM_004119:exon8:c.C956T:p.S319L		Likely Deleterious	FLT3	nonsynonymo us SNV	het
WM3901PLXMP3MouseN um6529	KIT:NM_000222:exon2:c.G152A:p.G51D		Likely Deleterious	KIT	nonsynonymo us SNV	het
WM3901PLXMP3MouseN um6529	PIK3CA:NM_006218:exon16:c.T2368C:p.S790P		VUS	PIK3C A	nonsynonymo us SNV	het
WM3901PLXMP4p7	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM3901PLXMP4p7	CDKN2A:NM_000077:exon2:c.197_219del:p.66_73del		Deleterious	CDKN 2A	frameshift deletion	het
WM3901PLXMP4p7	FLT3:NM_004119:exon8:c.C956T:p.S319L		Likely Deleterious	FLT3	nonsynonymo us SNV	het
WM3901PLXMP4p7	KIT:NM_000222:exon2:c.G152A:p.G51D		Likely Deleterious	KIT	nonsynonymo us SNV	het
WM3901PLXMP4p7	PIK3CA:NM_006218:exon16:c.T2368C:p.S790P		VUS	PIK3C A	nonsynonymo us SNV	het
WM3901PLXMP4p7	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM3903- 1MP5MouseNum4045	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM3903- 1MP5MouseNum4045	ERBB2:NM_004448:exon10:c.G1185C:p.E395D		VUS	ERBB 2	nonsynonymo us SNV	het
WM3903- 1MP5MouseNum4045	MAP2K1:NM_002755:exon2:c.A167C:p.Q56P		Deleterious	MAP2 K1	nonsynonymo us SNV	het
WM3903- 1MP5MouseNum4045	MAP2K1:NM_002755:exon2:c.G182A:p.G61E		VUS	MAP2 K1	nonsynonymo us SNV	het
WM3903- 1MP5MouseNum4045	PREX2:NM_024870:exon11:c.G1261A:p.E421K		Likely Deleterious	PREX 2	nonsynonymo us SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM3903-1MP5MouseNum4045	PREX2:NM_024870:exon29:c.C3577G:p.P1193A		VUS	PREX2	nonsynonymous SNV	het
WM3903-1MP5MouseNum4045	TERT Chr5:1295242 G>A		VUS	TERT	Promoter SNV	het
WM3903-1MP5MouseNum4045	TRRAP:NM_001244580:exon18:c.C2165T:p.S722F		VUS	TRRAP	nonsynonymous SNV	het
WM3903-1MP5MouseNum4045	VAV3:NM_006113:exon25:c.C2294T:p.P765L		Likely Deleterious	VAV3	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	APC:NM_001127511:exon14:c.G2380A:p.D794N		VUS	APC	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	ARID1A:NM_006015:exon2:c.C1174T:p.P392S		VUS	ARID1A	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	ATM:NM_000051:exon10:c.C1270T:p.P424S		Likely Deleterious	ATM	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	ATM:NM_000051:exon14:c.G2198A:p.G733D		VUS	ATM	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	ATM:NM_000051:exon59:c.C8602T:p.L2868F		Likely Deleterious	ATM	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	CDKN2B:NM_004936:exon2:c.G338A:p.G113D		Likely Deleterious	CDKN2B	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	DCC:NM_005215:exon18:c.G2786A:p.S929N		Likely Deleterious	DCC	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	ERBB3:NM_001982:exon12:c.G1355A:p.G452E		Likely Deleterious	ERBB3	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	ERBB4:NM_005235:exon13:c.G1540A:p.G514R		Likely Deleterious	ERBB4	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	FBXW7:NM_033632:exon4:c.G593A:p.G198E		VUS	FBXW7	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	FLT3:NM_004119:exon6:c.G718A:p.E240K		VUS	FLT3	nonsynonymous SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM3903-1MP6MouseNum6576	GNAI1:NM_002067:exon5:c.G727A:p.D243N		Likely Deleterious	GNAI1	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	GRM3:NM_000840:exon5:c.T2531A:p.F844Y		VUS	GRM3	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	IDH1:NM_005896:exon4:c.C152T:p.A51V		Likely Deleterious	IDH1	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	KDR:NM_002253:exon15:c.G2245A:p.E749K		Likely Deleterious	KDR	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	KDR:NM_002253:exon16:c.2353_2354del:p.I785fs		Deleterious	KDR	frameshift deletion	het
WM3903-1MP6MouseNum6576	MAP2K1:NM_002755:exon2:c.A167C:p.Q56P		Deleterious	MAP2K1	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	MDM4:NM_002393:exon5:c.C289T:p.P97S		Likely Deleterious	MDM4	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	MITF:NM_198159:exon6:c.C848T:p.A283V		VUS	MITF	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	NOTCH1:NM_017617:exon10:c.C1606T:p.P536S		Likely Deleterious	NOTCH1	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	NOTCH1:NM_017617:exon18:c.G2807A:p.G936D		Likely Deleterious	NOTCH1	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	NOTCH1:NM_017617:exon22:c.G3587A:p.G1196D		Likely Deleterious	NOTCH1	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	PREX2:NM_024870:exon5:c.C506T:p.P169L		Likely Deleterious	PREX2	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	SMO:NM_005631:exon10:c.C1678T:p.P560S		Likely Deleterious	SMO	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	TACC1:NM_006283:exon5:c.C1472T:p.S49IF		VUS	TACC1	nonsynonymous SNV	het
WM3903-1MP6MouseNum6576	TERT Chr5:1295228 G>A		Deleterious	TERT	Promoter SNV	hom
WM3903-1MP6MouseNum6576	VAV3:NM_006113:exon10:c.G964A:p.D322N		Likely Deleterious	VAV3	nonsynonymous SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM3903-1MP6PLXp15	APC:NM_001127511:exon14:c.G2380A:p.D794N		VUS	APC	nonsynonymo us SNV	het
WM3903-1MP6PLXp15	ARID1A:NM_006015:exon2:c.C1174T:p.P392S		VUS	ARID1 A	nonsynonymo us SNV	het
WM3903-1MP6PLXp15	ATM:NM_000051:exon10:c.C1270T:p.P424S		VUS	ATM	nonsynonymo us SNV	het
WM3903-1MP6PLXp15	ATM:NM_000051:exon14:c.G2198A:p.G733D		VUS	ATM	nonsynonymo us SNV	het
WM3903-1MP6PLXp15	ATM:NM_000051:exon59:c.C8602T:p.L2868F		Likely Deleterious	ATM	nonsynonymo us SNV	het
WM3903-1MP6PLXp15	BAP1:NM_004656:exon17:c.G2123A:p.R708Q		VUS	BAP1	nonsynonymo us SNV	het
WM3903-1MP6PLXp15	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM3903-1MP6PLXp15	CDKN2B:NM_004936:exon2:c.G338A:p.G113D		Likely Deleterious	CDKN 2B	nonsynonymo us SNV	hom
WM3903-1MP6PLXp15	DCC:NM_005215:exon18:c.G2786A:p.S929N		Likely Deleterious	DCC	nonsynonymo us SNV	het
WM3903-1MP6PLXp15	ERBB2:NM_004448:exon14:c.C1648T:p.L550F		VUS	ERBB 2	nonsynonymo us SNV	het
WM3903-1MP6PLXp15	ERBB3:NM_001982:exon12:c.G1355A:p.G452E		Likely Deleterious	ERBB 3	nonsynonymo us SNV	het
WM3903-1MP6PLXp15	ERBB4:NM_005235:exon13:c.G1540A:p.G514R		Likely Deleterious	ERBB 4	nonsynonymo us SNV	het
WM3903-1MP6PLXp15	FBXW7:NM_033632:exon4:c.G593A:p.G198E		VUS	FBXW 7	nonsynonymo us SNV	het
WM3903-1MP6PLXp15	GRM3:NM_000840:exon5:c.T2531A:p.F844Y		VUS	GRM3	nonsynonymo us SNV	het
WM3903-1MP6PLXp15	IDH1:NM_005896:exon4:c.C152T:p.A51V		Likely Deleterious	IDH1	nonsynonymo us SNV	het
WM3903-1MP6PLXp15	KDR:NM_002253:exon15:c.G2245A:p.E749K		Likely Deleterious	KDR	nonsynonymo us SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM3903-1IMP6PLXp15	KDR:NM_002253:exon16:c.2353_2354del:p.785_785del		Deleterious	KDR	frameshift deletion	het
WM3903-1IMP6PLXp15	MAP2K1(NM_002755:exon5:c.517-1G>A, p.V173_splice)		Likely Deleterious	MAP2K1	splicing	het
WM3903-1IMP6PLXp15	MAP2K1:NM_002755:exon2:c.A167C:p.Q56P		Deleterious	MAP2K1	nonsynonymous SNV	het
WM3903-1IMP6PLXp15	MAP3K5:NM_005923:exon17:c.G2369A:p.G790E		Likely Deleterious	MAP3K5	nonsynonymous SNV	hom
WM3903-1IMP6PLXp15	MDM4:NM_002393:exon5:c.C289T:p.P97S		Likely Deleterious	MDM4	nonsynonymous SNV	het
WM3903-1IMP6PLXp15	MITF:NM_198159:exon6:c.C848T:p.A283V		VUS	MITF	nonsynonymous SNV	het
WM3903-1IMP6PLXp15	NF1:NM_001042492:exon17:c.1877delT:p.L626fs		Deleterious	NF1	frameshift deletion	het
WM3903-1IMP6PLXp15	NOTCH1:NM_017617:exon10:c.C1606T:p.P536S		Likely Deleterious	NOTCH1	nonsynonymous SNV	het
WM3903-1IMP6PLXp15	NOTCH1:NM_017617:exon18:c.G2807A:p.G936D		Likely Deleterious	NOTCH1	nonsynonymous SNV	het
WM3903-1IMP6PLXp15	NOTCH1:NM_017617:exon22:c.G3587A:p.G1196D		Likely Deleterious	NOTCH1	nonsynonymous SNV	het
WM3903-1IMP6PLXp15	PREX2:NM_024870:exon5:c.C506T:p.P169L		Likely Deleterious	PREX2	nonsynonymous SNV	het
WM3903-1IMP6PLXp15	SMO:NM_005631:exon10:c.C1678T:p.P560S		Likely Deleterious	SMO	nonsynonymous SNV	het
WM3903-1IMP6PLXp15	TACC1:NM_006283:exon5:c.C1472T:p.S491F		VUS	TACC1	nonsynonymous SNV	het
WM3903-1IMP6PLXp15	TERT Chr5:1295228 G>A		Deleterious	TERT	Promoter SNV	hom
WM3903-1IMP6PLXp15	VAV3:NM_006113:exon10:c.G964A:p.D322N		Likely Deleterious	VAV3	nonsynonymous SNV	het
WM3907-1IMP3MouseNum3414	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	hom

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM3907-1MP3MouseNum3414	GRIN2A:NM_001134407:exon3:c.G536A:p.G179D		Likely Deleterious	GRIN2A	nonsynonymous SNV	het
WM3907-1MP3MouseNum3414	TRRAP:NM_001244580:exon27:c.C3871T:p.P129IS		Likely Deleterious	TRRAP	nonsynonymous SNV	het
WM3908MP3MouseNum1563RECUT	ARID1A:NM_006015:exon20:c.G6770A:p.R2257Q		Likely Deleterious	ARID1A	nonsynonymous SNV	het
WM3908MP3MouseNum1563RECUT	BRAF:NM_004333:exon15:c.GT1798AA:p.V600K		Deleterious	BRAF	nonsynonymous SNV	het
WM3908MP3MouseNum1563RECUT	CTNNB1:NM_001904:exon3:c.C134T:p.S45F		Deleterious	CTNNB1	nonsynonymous SNV	het
WM3908MP3MouseNum1563RECUT	FBXW7:NM_033632:exon2:c.349_351del:p.117_117del		Likely Deleterious	FBXW7	nonframeshift deletion	het
WM3908MP3MouseNum1563RECUT	GRM3:NM_000840:exon2:c.C65T:p.S22F		VUS	GRM3	nonsynonymous SNV	het
WM3908MP3MouseNum1563RECUT	IDH1:NM_005896:exon4:c.C394T:p.R132C		Deleterious	IDH1	nonsynonymous SNV	het
WM3908MP3MouseNum1563RECUT	SMARCA4:NM_001128849:exon6:c.C895T:p.P299S		VUS	SMARCA4	nonsynonymous SNV	het
WM3908MP3MouseNum1563RECUT	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM3908MP3MouseNum1563RECUT	VAV3:NM_006113:exon19:c.G1736A:p.R579Q		VUS	VAV3	nonsynonymous SNV	het
WM3908MP4PLXMouseNum6433RECUT	ARID1A:NM_006015:exon20:c.G6770A:p.R2257Q		Likely Deleterious	ARID1A	nonsynonymous SNV	het
WM3908MP4PLXMouseNum6433RECUT	BRAF:NM_004333:exon15:c.GT1798AA:p.V600K		Deleterious	BRAF	nonsynonymous SNV	het
WM3908MP4PLXMouseNum6433RECUT	CTNNB1:NM_001904:exon3:c.C134T:p.S45F		Deleterious	CTNNB1	nonsynonymous SNV	het
WM3908MP4PLXMouseNum6433RECUT	DDX3X:NM_001356:exon15:c.A1694C:p.Q565P		VUS	DDX3X	nonsynonymous SNV	het
WM3908MP4PLXMouseNum6433RECUT	FBXW7:NM_033632:exon2:c.349_351del:p.117_117del		Likely Deleterious	FBXW7	nonframeshift deletion	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM3908MP4PLXMouseN um6433RECUT	GRM3:NM_000840:exon2:c.C65T:p.S22F		VUS	GRM3	nonsynonymo us SNV	het
WM3908MP4PLXMouseN um6433RECUT	IDH1:NM_005896:exon4:c.C394T:p.R132C		Deleterious	IDH1	nonsynonymo us SNV	het
WM3908MP4PLXMouseN um6433RECUT	SMARCA4:NM_001128849:exon6:c.C895T:p.P29 9S		VUS	SMAR CA4	nonsynonymo us SNV	het
WM3908MP4PLXMouseN um6433RECUT	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM3908MP4PLXMouseN um6433RECUT	VAV3:NM_006113:exon19:c.G1736A:p.R579Q		VUS	VAV3	nonsynonymo us SNV	het
WM3909MP6MouseNum6 870	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM3909MP6MouseNum6 870	ROS1:NM_002944:exon30:c.C5035T:p.P1679S		VUS	ROS1	nonsynonymo us SNV	het
WM3909MP6MouseNum6 870	ROS1:NM_002944:exon6:c.C551T:p.P184L		VUS	ROS1	nonsynonymo us SNV	het
WM3909MP6MouseNum6 870	SMARCA4:NM_001128849:exon34:c.C4859T:p.S 1620F		VUS	SMAR CA4	nonsynonymo us SNV	het
WM3909PLX2MP7	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM3909PLX2MP7	ROS1:NM_002944:exon30:c.C5035T:p.P1679S		VUS	ROS1	nonsynonymo us SNV	het
WM3909PLX2MP7	ROS1:NM_002944:exon6:c.C551T:p.P184L		VUS	ROS1	nonsynonymo us SNV	het
WM3909PLX2MP7	SMARCA4:NM_001128849:exon34:c.C4859T:p.S 1620F		VUS	SMAR CA4	nonsynonymo us SNV	het
WM3909PLX2MP7	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM3926MP2MouseNum6 234	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM3926MP2MouseNum6 234	CDK4:NM_000075:exon2:c.C70T:p.R24C	Germline Susceptibility Mutation	Deleterious	CDK4	nonsynonymo us SNV	het
WM3926MP2MouseNum6 234	FLT3:NM_004119:exon3:c.C305T:p.S102F		VUS	FLT3	nonsynonymo us SNV	hom
WM3926MP2MouseNum6 234	PTEN(NM_000314:exon1:c.79+1G>A), p.Y27_splice		Likely Deleterious	PTEN	splicing	hom
WM3926MP2MouseNum6 234	PTPRD:NM_002839:exon33:c.G3875T:p.R1292M		VUS	PTPR D	nonsynonymo us SNV	hom
WM3926MP2MouseNum6 234	TERT chr5:1295205 G>A		VUS	TERT	Promoter SNV	het
WM3926MP2MouseNum6 234	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM3926MP3p5MouseNu m7864	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM3926MP3p5MouseNu m7864	CDK4:NM_000075:exon2:c.C70T:p.R24C	Germline Susceptibility Mutation	Deleterious	CDK4	nonsynonymo us SNV	het
WM3926MP3p5MouseNu m7864	FLT3:NM_004119:exon3:c.C305T:p.S102F		VUS	FLT3	nonsynonymo us SNV	hom _alt
WM3926MP3p5MouseNu m7864	PTEN:NM_000314:exon1:c.79+1G>A		Likely Deleterious	PTEN	splicing	hom _alt
WM3926MP3p5MouseNu m7864	PTPRD:NM_002839:exon33:c.G3875T:p.R1292M		VUS	PTPR D	nonsynonymo us SNV	hom _alt
WM3926MP3p5MouseNu m7864	TERT chr5:1295205 G>A		VUS	TERT	Promoter SNV	het
WM3926MP3p5MouseNu m7864	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM3926PLXMP4MouseN um8063	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM3926PLXMP4MouseN um8063	CDK4:NM_000075:exon2:c.C70T:p.R24C	Germline Susceptibility Mutation	Deleterious	CDK4	nonsynonymo us SNV	het
WM3926PLXMP4MouseN um8063	FLT3:NM_004119:exon3:c.C305T:p.S102F		VUS	FLT3	nonsynonymo us SNV	hom
WM3926PLXMP4MouseN um8063	PTEN(NM_000314:exon1:c.79+1G>A), p.Y27_splice		Likely Deleterious	PTEN	splicing	hom
WM3926PLXMP4MouseN um8063	PTPRD:NM_002839:exon33:c.G3875T:p.R1292M		VUS	PTPR D	nonsynonymo us SNV	hom
WM3926PLXMP4MouseN um8063	TERT chr5:1295205 G>A		VUS	TERT	Promoter SNV	het
WM3926PLXMP4MouseN um8063	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM3926PLXMP4PLXp10	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM3926PLXMP4PLXp10	CDK4:NM_000075:exon2:c.C70T:p.R24C		Likely Deleterious	CDK4	nonsynonymo us SNV	het
WM3926PLXMP4PLXp10	FLT3:NM_004119:exon3:c.C305T:p.S102F		VUS	FLT3	nonsynonymo us SNV	hom _alt
WM3926PLXMP4PLXp10	MAP2K1:NM_002755:exon3:c.G362C:p.C121S		Likely Deleterious	MAP2 K1	nonsynonymo us SNV	het
WM3926PLXMP4PLXp10	PTEN:NM_001304717:exon2:c.598+1G>A		Likely Deleterious	PTEN	splicing	hom _alt
WM3926PLXMP4PLXp10	PTPRD:NM_002839:exon33:c.G3875T:p.R1292M		VUS	PTPR D	nonsynonymo us SNV	hom _alt
WM3926PLXMP4PLXp10	TERT chr5:1295205 G>A		VUS	TERT	Promoter SNV	hom _alt
WM3926PLXMP4PLXp10	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	hom _alt
WM3929MCP4PLXMP7p6M ouseNum6538	ALK:NM_004304:exon15:c.G2579C:p.R860T		Likely Deleterious	ALK	nonsynonymo us SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM3929MCPLXMP7p6M ouseNum6538	BRAF:NM_004333:exon13:c.C1624T:p.H542Y		Deleterious	BRAF	nonsynonymo us SNV	het
WM3929MCPLXMP7p6M ouseNum6538	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM3929MCPLXMP7p6M ouseNum6538	CDKN2A:NM_000077:exon2:c.C341T:p.P114L		Deleterious	CDKN 2A	nonsynonymo us SNV	hom
WM3929MCPLXMP7p6M ouseNum6538	EZH1:NM_001991:exon12:c.C1336T:p.H446Y		VUS	EZH1	nonsynonymo us SNV	het
WM3929MCPLXMP7p6M ouseNum6538	FLT3:NM_004119:exon3:c.G296A:p.G99E		VUS	FLT3	nonsynonymo us SNV	het
WM3929MCPLXMP7p6M ouseNum6538	JAK3:NM_000215:exon8:c.C1094T:p.P365L		VUS	JAK3	nonsynonymo us SNV	hom
WM3929MCPLXMP7p6M ouseNum6538	PTPRD:NM_002839:exon29:c.C3073T:p.H1025Y		VUS	PTPR D	nonsynonymo us SNV	hom
WM3929MCPLXMP7p6M ouseNum6538	SOX10:NM_006941:exon2:c.A191C:p.D64A		VUS	SOX1 0	nonsynonymo us SNV	het
WM3929MCPLXMP7p6M ouseNum6538	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM3929MCPLXMP7p6M ouseNum6538	TP53:NM_000546:exon5:c.T428G:p.V143G		Deleterious	TP53	nonsynonymo us SNV	hom
WM3929PLXMP5PLXp15	ALK:NM_004304:exon15:c.G2579C:p.R860T		Likely Deleterious	ALK	nonsynonymo us SNV	het
WM3929PLXMP5PLXp15	BRAF:NM_004333:exon13:c.C1624T:p.H542Y		Likely Deleterious	BRAF	nonsynonymo us SNV	het
WM3929PLXMP5PLXp15	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM3929PLXMP5PLXp15	CDKN2A:NM_000077:exon2:c.C341T:p.P114L		Deleterious	CDKN 2A	nonsynonymo us SNV	hom _alt
WM3929PLXMP5PLXp15	CTNNA1:NM_001904:exon3:c.123_149del:p.41_50del		Likely Deleterious	CTNN B1	nonframeshift deletion	het
WM3929PLXMP5PLXp15	EZH1:NM_001991:exon12:c.C1336T:p.H446Y		VUS	EZH1	nonsynonymo us SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM3929PLXMP5PLXp15	FLT3:NM_004119:exon3:c.G296A:p.G99E		VUS	FLT3	nonsynonymous SNV	het
WM3929PLXMP5PLXp15	JAK3:NM_000215:exon8:c.C1094T:p.P365L		Likely Deleterious	JAK3	nonsynonymous SNV	hom
WM3929PLXMP5PLXp15	PTPRD:NM_002839:exon29:c.C3073T:p.H1025Y		VUS	PTPRD	nonsynonymous SNV	hom
WM3929PLXMP5PLXp15	SOX10:NM_006941:exon2:c.A191C:p.D64A		Likely Deleterious	SOX10	nonsynonymous SNV	het
WM3929PLXMP5PLXp15	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM3929PLXMP5PLXp15	TP53:NM_000546:exon5:c.T428G:p.V143G		Deleterious	TP53	nonsynonymous SNV	hom
WM3935MP1MouseNum1752	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	het
WM3935MP1MouseNum1752	CDKN2A:NM_000077:exon2:c.T389A:p.L130Q		Likely Deleterious	CDKN2A	nonsynonymous SNV	hom
WM3935MP1MouseNum1752	CTNNB1:NM_001904:exon9:c.G1358A:p.R453Q		VUS	CTNNB1	nonsynonymous SNV	het
WM3935MP1MouseNum1752	KDR:NM_002253:exon21:c.G2824A:p.G942R		Likely Deleterious	KDR	nonsynonymous SNV	het
WM3935MP1MouseNum1752	MAP3K5:NM_005923:exon30:c.G4093A:p.A1365T		Likely Deleterious	MAP3K5	nonsynonymous SNV	hom
WM3935MP1MouseNum1752	NF2:NM_000268:exon14:c.C1448T:p.P483L		VUS	NF2	nonsynonymous SNV	het
WM3935MP1MouseNum1752	SMARCA4:NM_001128849:exon29:c.G3976A:p.E1326K		Likely Deleterious	SMARCA4	nonsynonymous SNV	het
WM3935MP1MouseNum1752	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM3935MP1MouseNum1752	TERT:NM_198253:exon5:c.G2006A:p.R669Q		Likely Deleterious	TERT	nonsynonymous SNV	het
WM3935MP1MouseNum1752	TP53:NM_000546:exon5:c.G542A:p.R181H		Deleterious	TP53	nonsynonymous SNV	hom

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM3936- 1MP3PLXp4MouseNum38 50	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM3936- 1MP3PLXp4MouseNum38 50	NRAS:NM_002524:exon3:c.C181A:p.Q61K		Deleterious	NRAS	nonsynonymo us SNV	het
WM3936- 1MP3PLXp4MouseNum38 50	PIK3CA:NM_006218:exon21:c.C3139T:p.H1047 Y		Deleterious	PIK3C A	nonsynonymo us SNV	het
WM3936- 1MP3PLXp4MouseNum38 50	PTEN:NM_000314:exon5:c.G314A:p.C105Y		Likely Deleterious	PTEN	nonsynonymo us SNV	hom
WM3936- 1MP3PLXp4MouseNum38 50	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM3936- 2MP1MouseNum2975REC UT	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM3936- 2MP1MouseNum2975REC UT	NRAS:NM_002524:exon3:c.C181A:p.Q61K		Deleterious	NRAS	nonsynonymo us SNV	het
WM3936- 2MP1MouseNum2975REC UT	PIK3CA:NM_006218:exon21:c.C3139T:p.H1047 Y		Deleterious	PIK3C A	nonsynonymo us SNV	het
WM3936- 2MP1MouseNum2975REC UT	PTEN:NM_000314:exon5:c.G314A:p.C105Y		Likely Deleterious	PTEN	nonsynonymo us SNV	het
WM3936- 2MP5MouseNum3646	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM3936- 2MP5MouseNum3646	NRAS:NM_002524:exon3:c.C181A:p.Q61K		Deleterious	NRAS	nonsynonymo us SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM3936- 2MP5MouseNum3646	PIK3CA:NM_006218:exon21:c.C3139T:p.H1047Y		Deleterious	PIK3CA	nonsynonymo us SNV	het
WM3936- 2MP5MouseNum3646	PTEN:NM_000314:exon5:c.G314A:p.C105Y		Likely Deleterious	PTEN	nonsynonymo us SNV	hom
WM3939- 2CPLXMP5p7MouseNum 5183	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM3939- 2CPLXMP5p7MouseNum 5183	ERBB2:NM_004448:exon10:c.G1185C:p.E395D		VUS	ERBB2	nonsynonymo us SNV	het
WM3939- 2CPLXMP5p7MouseNum 5183	MAP2K1:NM_002755:exon2:c.A167C:p.Q56P		Deleterious	MAP2K1	nonsynonymo us SNV	het
WM3939- 2CPLXMP5p7MouseNum 5183	MAP2K1:NM_002755:exon2:c.G182A:p.G61E		VUS	MAP2K1	nonsynonymo us SNV	het
WM3939- 2CPLXMP5p7MouseNum 5183	MAP2K2:NM_030662:exon3:c.G426C:p.E142D		Likely Deleterious	MAP2K2	nonsynonymo us SNV	het
WM3939- 2CPLXMP5p7MouseNum 5183	PREX2:NM_024870:exon11:c.G1261A:p.E421K		Likely Deleterious	PREX2	nonsynonymo us SNV	het
WM3939- 2CPLXMP5p7MouseNum 5183	PREX2:NM_024870:exon29:c.C3577G:p.P1193A		VUS	PREX2	nonsynonymo us SNV	het
WM3939- 2CPLXMP5p7MouseNum 5183	TERT Chr5:1295242-1295243 GG>AA		Deleterious	TERT	Promoter SNV	het
WM3939- 2CPLXMP5p7MouseNum 5183	TRRAP:NM_001244580:exon18:c.C2165T:p.S722F		Likely Deleterious	TRRAP	nonsynonymo us SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX						
Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM3939-2CPLXMP5p7MouseNum5183	VAV3:NM_006113:exon25:c.C2294T:p.P765L		Likely Deleterious	VAV3	nonsynonymous SNV	het
WM3939-2CPLXMP6MouseNum5900	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	het
WM3939-2CPLXMP6MouseNum5900	ERBB2:NM_004448:exon10:c.G1185C:p.E395D		VUS	ERBB2	nonsynonymous SNV	het
WM3939-2CPLXMP6MouseNum5900	MAP2K1:NM_002755:exon2:c.A167C:p.Q56P		Deleterious	MAP2K1	nonsynonymous SNV	het
WM3939-2CPLXMP6MouseNum5900	MAP2K1:NM_002755:exon2:c.G182A:p.G6IE		VUS	MAP2K1	nonsynonymous SNV	het
WM3939-2CPLXMP6MouseNum5900	PREX2:NM_024870:exon11:c.G1261A:p.E421K		Likely Deleterious	PREX2	nonsynonymous SNV	het
WM3939-2CPLXMP6MouseNum5900	PREX2:NM_024870:exon29:c.C3577G:p.P1193A		VUS	PREX2	nonsynonymous SNV	het
WM3939-2CPLXMP6MouseNum5900	TERT Chr5:1295242 G>A		VUS	TERT	Promoter SNV	het
WM3939-2CPLXMP6MouseNum5900	TRRAP:NM_001244580:exon18:c.C2165T:p.S722F		VUS	TRRAP	nonsynonymous SNV	het
WM3939-2CPLXMP6MouseNum5900	VAV3:NM_006113:exon25:c.C2294T:p.P765L		Likely Deleterious	VAV3	nonsynonymous SNV	het
WM3942CPLXMP3MouseNum8885	ABL1:NM_005157:exon6:c.G1015C:p.V339L		Likely Deleterious	ABL1	nonsynonymous SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM3942CPLXMP3Mouse Num8885	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM3942CPLXMP3Mouse Num8885	MAP2K2:NM_030662:exon3:c.T373A:p.C125S		Deleterious	MAP2K2	nonsynonymo us SNV	het
WM3942CPLXMP3Mouse Num8885	PIK3CB:NM_006219:exon4:c.T694G:p.L232V		VUS	PIK3CB	nonsynonymo us SNV	het
WM3942CPLXMP3Mouse Num8885	TERT Chr5:1295228 G>A		Deleterious	TERT	Promoter SNV	het
WM3942MP3p5MouseNum m8752	ABL1:NM_005157:exon6:c.G1015C:p.V339L		Likely Deleterious	ABL1	nonsynonymo us SNV	het
WM3942MP3p5MouseNum m8752	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM3942MP3p5MouseNum m8752	PIK3CB:NM_006219:exon4:c.T694G:p.L232V		VUS	PIK3CB	nonsynonymo us SNV	het
WM3942MP3p5MouseNum m8752	TERT Chr5:1295228 G>A		Deleterious	TERT	Promoter SNV	het
WM3960CPLXMP4Mouse Num5838	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	hom
WM3960CPLXMP4Mouse Num5838	PTPRD:NM_002839:exon28:c.G3023A:p.S1008N		VUS	PTPRD	nonsynonymo us SNV	hom
WM3960CPLXMP4p4	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	hom _alt
WM3960CPLXMP4p4	PTPRD:NM_002839:exon28:c.G3023A:p.S1008N		VUS	PTPRD	nonsynonymo us SNV	hom _alt
WM3960CPLXMP4p4	TERT Chr5:1295228 G>A		Deleterious	TERT	Promoter SNV	hom _alt
WM3960MP2PLXp20Mou seNum3448	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	hom _alt
WM3960MP2PLXp20Mou seNum3448	NRAS:NM_002524:exon3:c.C181A:p.Q61K		Deleterious	NRAS	nonsynonymo us SNV	het
WM3960MP2PLXp20Mou seNum3448	PTPRD:NM_002839:exon28:c.G3023A:p.S1008N		VUS	PTPRD	nonsynonymo us SNV	hom _alt

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM3960MP2PLXp20MouseNum3448	TERT Chr5:1295228 G>A		Deleterious	TERT	Promoter SNV	hom _alt
WM3960MP4MouseNum3960	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	hom
WM3960MP4MouseNum3960	PTPRD:NM_002839:exon28:c.G3023A:p.S1008N		VUS	PTPRD	nonsynonymous SNV	hom
WM3960MP4MouseNum3960	TERT Chr5:1295228 G>A		Deleterious	TERT	Promoter SNV	hom
WM3965-2MP1MouseNum3054	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	het
WM3973MP3MouseNum3470	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	hom
WM3973MP3MouseNum3470	DDX3X:NM_001356:exon2:c.92_93insTAs:p.S31fs		Deleterious	DDX3X	frameshift insertion	hom
WM3973MP3MouseNum3470	MAP2K1:NM_002755:exon2:c.A169G:p.K57E		Deleterious	MAP2K1	nonsynonymous SNV	het
WM3973MP3MouseNum3470	MAP2K1:NM_002755:exon6:c.G605A:p.G202E		Likely Deleterious	MAP2K1	nonsynonymous SNV	het
WM3973MP3MouseNum3470	RHOT1:NM_001033568:exon11:c.C865T:p.P289S		Likely Deleterious	RHOT1	nonsynonymous SNV	het
WM3973MP3MouseNum3470	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM3973MP4MouseNum7144	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	het
WM3973MP4MouseNum7144	DDX3X:NM_001356:exon2:c.92_93insTAs:p.S31fs		Deleterious	DDX3X	frameshift insertion	het
WM3973MP4MouseNum7144	MAP2K1:NM_002755:exon2:c.A169G:p.K57E		Deleterious	MAP2K1	nonsynonymous SNV	het
WM3973MP4MouseNum7144	MAP2K1:NM_002755:exon6:c.G605A:p.G202E		Likely Deleterious	MAP2K1	nonsynonymous SNV	het
WM3973MP4MouseNum7144	RHOT1:NM_001033568:exon11:c.C865T:p.P289S		Likely Deleterious	RHOT1	nonsynonymous SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM3973MP4MouseNum7144	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM3973PLXMP5MouseN um7627	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	het
WM3973PLXMP5MouseN um7627	DDX3X:NM_001356:exon2:c.92_93insTAs:p.S31fs		Deleterious	DDX3X	frameshift insertion	het
WM3973PLXMP5MouseN um7627	MAP2K1:NM_002755:exon2:c.A169G:p.K57E		Deleterious	MAP2K1	nonsynonymous SNV	het
WM3973PLXMP5MouseN um7627	MAP2K1:NM_002755:exon6:c.G605A:p.G202E		Likely Deleterious	MAP2K1	nonsynonymous SNV	het
WM3973PLXMP5MouseN um7627	RHOT1:NM_001033568:exon11:c.C865T:p.P289S		Likely Deleterious	RHOT1	nonsynonymous SNV	het
WM3973PLXMP5MouseN um7627	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM3983PLXMP7MouseN um8003	ARID1A:NM_006015:exon1:c.G707T:p.G236V		VUS	ARID1A	nonsynonymous SNV	het
WM3983PLXMP7MouseN um8003	ATM:NM_000051:exon60:c.C8708T:p.P2903L		Likely Deleterious	ATM	nonsynonymous SNV	het
WM3983PLXMP7MouseN um8003	BRAF:NM_004333:exon15:c.T1799A:p.V600K		Deleterious	BRAF	nonsynonymous SNV	het
WM3983PLXMP7MouseN um8003	EGFR:NM_005228:exon10:c.C1190T:p.T397I		Likely Deleterious	EGFR	nonsynonymous SNV	het
WM3983PLXMP7MouseN um8003	EZH1:NM_001991:exon16:c.A1834G:p.K612E		Likely Deleterious	EZH1	nonsynonymous SNV	het
WM3983PLXMP7MouseN um8003	NRAS:NM_002524:exon3:c.C181A:p.Q61K		Deleterious	NRAS	nonsynonymous SNV	het
WM3983PLXMP7MouseN um8003	PPP6C:NM_001123355:exon8:c.C901T:p.R301C		VUS	PPP6C	nonsynonymous SNV	het
WM3983PLXMP7MouseN um8003	PREX2:NM_024870:exon4:c.C349T:p.R117C		VUS	PREX2	nonsynonymous SNV	het
WM3983PLXMP7MouseN um8003	SETD2:NM_014159:exon3:c.C2164T:p.Q722X		Deleterious	SETD2	stopgain	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM3983PLXMP7MouseNum8003	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	hom
WM3983PLXMP7MouseNum8003	TRRAP:NM_001244580:exon62:c.C9584T:p.S3195L		Likely Deleterious	TRRAP	nonsynonymous SNV	het
WM4008MP2MouseNum4345	ATM:NM_000051:exon47:c.G6912T:p.E2304D		Likely Deleterious	ATM	nonsynonymous SNV	het
WM4008MP2MouseNum4345	BRAF:NM_004333:exon15:c.GT1798AA:p.V600K		Deleterious	BRAF	nonsynonymous SNV	het
WM4008MP2MouseNum4345	PREX2:NM_024870:exon6:c.G637A:p.E213K		Likely Deleterious	PREX2	nonsynonymous SNV	het
WM4008MP2MouseNum4345	RB1:NM_000321:exon25:c.A2635T:p.I879F		Likely Deleterious	RB1	nonsynonymous SNV	het
WM4008MP2MouseNum4345	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM4008MP47433	ATM:NM_000051:exon47:c.G6912T:p.E2304D		Likely Deleterious	ATM	nonsynonymous SNV	het
WM4008MP47433	BRAF:NM_004333:exon15:c.T1799A:p.V600K		Deleterious	BRAF	nonsynonymous SNV	het
WM4008MP47433	PREX2:NM_024870:exon6:c.G637A:p.E213K		Likely Deleterious	PREX2	nonsynonymous SNV	het
WM4008MP47433	RB1:NM_000321:exon25:c.A2635T:p.I879F		Likely Deleterious	RB1	nonsynonymous SNV	het
WM4008MP47433	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM4018-7MP1MouseNum0332	APC:NM_001127511:exon14:c.C8362G:p.P2788A		Likely Deleterious	APC	nonsynonymous SNV	het
WM4018-7MP1MouseNum0332	BRAF:NM_004333:exon15:c.GT1798AA:p.V600K		Deleterious	BRAF	nonsynonymous SNV	het
WM4018-7MP1MouseNum0332	BRCA1:NM_007294:exon10:c.3891_3893del:p.1297_1298del		Likely Deleterious	BRCA1	nonframeshift deletion	het
WM4018-7MP1MouseNum0332	GRM3:NM_000840:exon3:c.G835A:p.D279N		Likely Deleterious	GRM3	nonsynonymous SNV	hom

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM4018- 7MP1MouseNum0332	RAC1:NM_006908:exon2:c.C85T;p.P29S		Deleterious	RAC1	nonsynonymous SNV	het
WM4018- 7MP1MouseNum0332	TERT Chr5:1295242 G>A		VUS	TERT	Promoter SNV	het
WM4018- 7MP1MouseNum0332	TP53:NM_000546:exon5:c.T518G;p.V173G		VUS	TP53	nonsynonymous SNV	het
WM4070- 2MP4MouseNum6758	BRAF:NM_004333:exon15:c.GT1798AA;p.V600K		Deleterious	BRAF	nonsynonymous SNV	het
WM4070- 2MP4MouseNum6758	DCC:NM_005215:exon10:c.G1685A;p.R562K		VUS	DCC	nonsynonymous SNV	het
WM4070- 2MP4MouseNum6758	DCC:NM_005215:exon19:c.C2837T;p.S946F		Likely Deleterious	DCC	nonsynonymous SNV	het
WM4070- 2MP4MouseNum6758	DCC:NM_005215:exon2:c.G164A;p.G55E		Likely Deleterious	DCC	nonsynonymous SNV	het
WM4070- 2MP4MouseNum6758	ERBB4:NM_005235:exon2:c.A94T;p.T32S		VUS	ERBB4	nonsynonymous SNV	het
WM4070- 2MP4MouseNum6758	MAP2K1:NM_002755:exon3:c.C370T;p.P124S		Likely Deleterious	MAP2K1	nonsynonymous SNV	het
WM4070- 2MP4MouseNum6758	MAP3K9:NM_033141:exon5:c.G1294A;p.E432K		VUS	MAP3K9	nonsynonymous SNV	het
WM4070- 2MP4MouseNum6758	PTPRD:NM_002839:exon20:c.G854A;p.G285E		Likely Deleterious	PTPRD	nonsynonymous SNV	het
WM4070- 2MP4MouseNum6758	TERT Chr5:1295228 G>A		Deleterious	TERT	Promoter SNV	het
WM4071- 1MP2MouseNum6673	BRAF:NM_004333:exon15:c.T1799A;p.V600E		Deleterious	BRAF	nonsynonymous SNV	het
WM4071- 1MP2MouseNum6673	PTEN:NM_000314:exon6:c.546dupA;p.L182fs		Deleterious	PTEN	frameshift insertion	hom
WM4071- 1MP2MouseNum6673	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM4071-1PLXMP3p5MouseNum73 ₂₈	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	het
WM4071-1PLXMP3p5MouseNum73 ₂₈	PTEN:NM_000314:exon6:c.546dupA:p.L182fs		Deleterious	PTEN	frameshift insertion	hom
WM4071-1PLXMP3p5MouseNum73 ₂₈	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM4071-2MP2717	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	het
WM4071-2MP2717	PTEN:NM_000314:exon6:c.546dupA:p.L182fs		Deleterious	PTEN	frameshift insertion	hom
WM4071-2MP2717	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM4071-2MP2p5MouseNum7116	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	het
WM4071-2MP2p5MouseNum7116	PTEN:NM_000314:exon6:c.546dupA:p.L182fs		Deleterious	PTEN	frameshift insertion	hom
WM4071-2MP2p5MouseNum7116	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM4071-2PLXMP2p6	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	het
WM4071-2PLXMP2p6	PTEN:NM_001304717:exon7:c.1065dupA:p.L355fs		Deleterious	PTEN	frameshift insertion	hom
WM4071-2PLXMP2p6	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM4205-1MP2PLXp7	ARID2:NM_152641:exon15:c.T4196A:p.L1399X		Deleterious	ARID2	stopgain	het
WM4205-1MP2PLXp7	BRAF:NM_004333:exon15:c.1799_1801del:p.600_601del		Likely Deleterious	BRAF	nonframeshift deletion	het
WM4205-1MP2PLXp7	PREX2:NM_024870:exon8:c.C889T:p.R297C		VUS	PREX2	nonsynonymous SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM4205-1MP2PLXp7	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM4205-2PLXMP3MouseNum8835	ARID2:NM_152641:exon15:c.T4196A:p.L1399X		Deleterious	ARID2	stopgain	het
WM4205-2PLXMP3MouseNum8835	BRAF:NM_004333:exon15:c.1799_1801del:p.600_601del (p.V600_K601delinsE)		Deleterious	BRAF	nonframeshift deletion	het
WM4205-2PLXMP3MouseNum8835	PREX2:NM_024870:exon8:c.C889T:p.R297C		VUS	PREX2	nonsynonymous SNV	het
WM4205-2PLXMP3MouseNum8835	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM4205-3MP1p4MouseNum6770	ARID2:NM_152641:exon15:c.T4196A:p.L1399X		Deleterious	ARID2	stopgain	het
WM4205-3MP1p4MouseNum6770	BRAF:NM_004333:exon15:c.1799_1801del:p.600_601del (p.V600_K601delinsE)		Deleterious	BRAF	nonframeshift deletion	hom
WM4205-3MP1p4MouseNum6770	PREX2:NM_024870:exon8:c.C889T:p.R297C		VUS	PREX2	nonsynonymous SNV	het
WM4205-3MP1p4MouseNum6770	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM4205-3MP2MouseNum7681	ARID2:NM_152641:exon15:c.T4196A:p.L1399X		Deleterious	ARID2	stopgain	het
WM4205-3MP2MouseNum7681	BRAF:NM_004333:exon15:c.1799_1801del:p.600_601del (p.V600_K601delinsE)		Deleterious	BRAF	nonframeshift deletion	het
WM4205-3MP2MouseNum7681	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM4205-3PLXMP2p36	ARID2:NM_152641:exon15:c.T4196A:p.L1399X		Deleterious	ARID2	stopgain	het
WM4205-3PLXMP2p36	BRAF:NM_004333:exon15:c.1799_1801del:p.600_601del (p.V600_K601delinsE)		Deleterious	BRAF	nonframeshift deletion	hom
WM4205-3PLXMP2p36	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM4237-3MP1MouseNum1093	ATM:NM_000051:exon55:c.C8071T:p.R2691C		Likely Deleterious	ATM	nonsynonymous SNV	hom

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM4237-3MP1 MouseNum1093	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	het
WM4237-3MP1 MouseNum1093	MET:NM_001127500:exon3:c.T1286C:p.L429S		Likely Deleterious	MET	nonsynonymous SNV	het
WM4237-3MP1 MouseNum1093	PDGFRA:NM_006206:exon5:c.G723T:p.E241D		Likely Deleterious	PDGFRA	nonsynonymous SNV	hom
WM4237-3MP1 MouseNum1093	RBI:NM_000321:exon20:c.2069_2082del:p.N690fs		Deleterious	RBI	frameshift deletion	het
WM4237-3MP1 MouseNum1093	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM4237-3MP1 MouseNum1093	TP53:NM_000546:exon7:c.C722T:p.S241F		Deleterious	TP53	nonsynonymous SNV	hom
WM4237-4MP1 MouseNum1730	ATM:NM_000051:exon55:c.C8071T:p.R2691C		Likely Deleterious	ATM	nonsynonymous SNV	hom
WM4237-4MP1 MouseNum1730	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	het
WM4237-4MP1 MouseNum1730	MET:NM_001127500:exon3:c.T1286C:p.L429S		Likely Deleterious	MET	nonsynonymous SNV	het
WM4237-4MP1 MouseNum1730	PDGFRA:NM_006206:exon5:c.G723T:p.E241D		Likely Deleterious	PDGFRA	nonsynonymous SNV	hom
WM4237-4MP1 MouseNum1730	PTPRD:NM_002839:exon43:c.C5266T:p.Q1756X		Deleterious	PTPRD	stopgain	het
WM4237-4MP1 MouseNum1730	RBI:NM_000321:exon20:c.2069_2082del:p.N690fs		Deleterious	RBI	frameshift deletion	hom
WM4237-4MP1 MouseNum1730	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM4237-4MP1 MouseNum1730	TP53:NM_000546:exon7:c.C722T:p.S241F		Deleterious	TP53	nonsynonymous SNV	hom
WM4237MP2p5	ATM:NM_000051:exon55:c.C8071T:p.R2691C		Likely Deleterious	ATM	nonsynonymous SNV	hom
WM4237MP2p5	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX						
Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM4237MP2p5	MET:NM_001127500:exon3:c.T1286C:p.L429S		Likely Deleterious	MET	nonsynonymo us SNV	het
WM4237MP2p5	PDGFRA:NM_006206:exon5:c.G723T:p.E241D		Likely Deleterious	PDGF RA	nonsynonymo us SNV	hom _alt
WM4237MP2p5	PTPRD:NM_002839:exon43:c.C5266T:p.Q1756X		Deleterious	PTPR D	stopgain	het
WM4237MP2p5	RBI:NM_000321:exon20:c.2069_2082del:p.N690f s		Deleterious	RBI	frameshift deletion	hom _alt
WM4237MP2p5	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM4237MP2p5	TP53:NM_000546:exon7:c.C722T:p.S241F		Deleterious	TP53	nonsynonymo us SNV	hom _alt
WM4239MP1MouseNum8 082	ARID1A:NM_006015:exon5:c.T1999C:p.S667P		Likely Deleterious	ARID1 A	nonsynonymo us SNV	hom _alt
WM4239MP1MouseNum8 082	BAP1:NM_004656:exon7:c.C505T:p.H169Y		Likely Deleterious	BAP1	nonsynonymo us SNV	het
WM4239MP1MouseNum8 082	BRAF:NM_004333:exon15:c.GT1798- 1799AA:p.V600K		Deleterious	BRAF	nonsynonymo us SNV	het
WM4239MP1MouseNum8 082	CDKN2A:NM_000077:exon2:c.C341T:p.P114L		Deleterious	CDKN 2A	nonsynonymo us SNV	hom _alt
WM4239MP1MouseNum8 082	DCC:NM_005215:exon13:c.C2027A:p.P676Q		Likely Deleterious	DCC	nonsynonymo us SNV	het
WM4239MP1MouseNum8 082	MET:NM_001127500:exon2:c.G1132A:p.V378I		Likely Deleterious	MET	nonsynonymo us SNV	het
WM4239MP1MouseNum8 082	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM4249MP1MouseNum8 724	APC:NM_001127511:exon14:c.C3329T:p.S1110F		VUS	APC	nonsynonymo us SNV	het
WM4249MP1MouseNum8 724	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM4249MP1MouseNum8 724	DCC:NM_005215:exon2:c.G164A:p.G55E		VUS	DCC	nonsynonymo us SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM4249MP1MouseNum8 724	DDX3X:NM_001356:exon8:c.T730G:p.S244A		VUS	DDX3X	nonsynonymo us SNV	het
WM4249MP1MouseNum8 724	GRIN2A:NM_001134407:exon13:c.C4238T:p.S1413F		Likely Deleterious	GRIN2A	nonsynonymo us SNV	het
WM4249MP1MouseNum8 724	JAK3:NM_000215:exon24:c.G3233A:p.W1078X		VUS	JAK3	stopgain	het
WM4249MP1MouseNum8 724	MAP2K2:NM_030662:exon7:c.C889T:p.R297W		Likely Deleterious	MAP2K2	nonsynonymo us SNV	het
WM4249MP1MouseNum8 724	NRAS:NM_002524:exon2:c.C67A:p.L23I		Likely Deleterious	NRAS	nonsynonymo us SNV	het
WM4249MP1MouseNum8 724	PDGFRA:NM_006206:exon8:c.G1156A:p.E386K		VUS	PDGFRA	nonsynonymo us SNV	het
WM4249MP1MouseNum8 724	PREX2:NM_024870:exon19:c.G2107A:p.G703R		VUS	PREX2	nonsynonymo us SNV	het
WM4249MP1MouseNum8 724	PTPRD:NM_002839:exon24:c.C1825T:p.P609S		Likely Deleterious	PTPRD	nonsynonymo us SNV	het
WM4249MP1MouseNum8 724	PTPRD:NM_002839:exon28:c.C2735T:p.S912F		Likely Deleterious	PTPRD	nonsynonymo us SNV	het
WM4249MP1MouseNum8 724	RB1:NM_000321:exon26:c.G2678C:p.G893A		VUS	RB1	nonsynonymo us SNV	het
WM4249MP1MouseNum8 724	SETD2:NM_014159:exon8:c.C4970T:p.P1657L		Likely Deleterious	SETD2	nonsynonymo us SNV	het
WM4249MP1MouseNum8 724	SMARCA4:NM_001128849:exon19:c.T2827C:p.F943L		Likely Deleterious	SMARCA4	nonsynonymo us SNV	het
WM4249MP1MouseNum8 724	SOX10:NM_006941:exon3:c.G472A:p.E158K		Likely Deleterious	SOX10	nonsynonymo us SNV	het
WM4249PLXMP2PLXp7 MouseNum8638	APC:NM_001127511:exon14:c.C3329T:p.S1110F		VUS	APC	nonsynonymo us SNV	het
WM4249PLXMP2PLXp7 MouseNum8638	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM4249PLXMP2PLXp7 MouseNum8638	DCC:NM_005215:exon2:c.G164A:p.G55E		Likely Deleterious	DCC	nonsynonymo us SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM4249PLXMP2PLXp7 MouseNum8638	GRIN2A:NM_001134407:exon13:c.C4238T:p.S1413F		Likely Deleterious	GRIN2A	nonsynonymous SNV	het
WM4249PLXMP2PLXp7 MouseNum8638	JAK3:NM_000215:exon24:c.G3233A:p.W1078X		VUS	JAK3	stopgain	het
WM4249PLXMP2PLXp7 MouseNum8638	MAP2K2:NM_030662:exon7:c.C889T:p.R297W		Likely Deleterious	MAP2K2	nonsynonymous SNV	het
WM4249PLXMP2PLXp7 MouseNum8638	PDGFRA:NM_006206:exon8:c.G1156A:p.E386K		VUS	PDGFRA	nonsynonymous SNV	het
WM4249PLXMP2PLXp7 MouseNum8638	PREX2:NM_024870:exon19:c.G2107A:p.G703R		Likely Deleterious	PREX2	nonsynonymous SNV	het
WM4249PLXMP2PLXp7 MouseNum8638	PTPRD:NM_002839:exon24:c.C1825T:p.P609S		Likely Deleterious	PTPRD	nonsynonymous SNV	het
WM4249PLXMP2PLXp7 MouseNum8638	PTPRD:NM_002839:exon28:c.C2735T:p.S912F		Likely Deleterious	PTPRD	nonsynonymous SNV	het
WM4249PLXMP2PLXp7 MouseNum8638	SETD2:NM_014159:exon8:c.C4970T:p.P1657L		Likely Deleterious	SETD2	nonsynonymous SNV	het
WM4249PLXMP2PLXp7 MouseNum8638	SMARCA4:NM_001128849:exon19:c.T2827C:p.F943L		Likely Deleterious	SMARCA4	nonsynonymous SNV	het
WM4249PLXMP2PLXp7 MouseNum8638	SOX10:NM_006941:exon3:c.G472A:p.E158K		Likely Deleterious	SOX10	nonsynonymous SNV	het
WM4258- 2MP1MouseNum1596	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	het
WM4258- 2MP1MouseNum1596	FGFR3:NM_000142:exon18:c.C2291T:p.S764L		Likely Deleterious	FGFR3	nonsynonymous SNV	hom _alt
WM4258- 2MP1MouseNum1596	PRCI:NM_003981:exon3:c.T206C:p.I69T		Likely Deleterious	PRCI	nonsynonymous SNV	het
WM4258- 2MP1MouseNum1596	RB1:NM_000321:exon14:c.C1363T:p.R455X		Deleterious	RB1	stopgain	hom _alt
WM4258- 2MP1MouseNum1596	TERT Chr5:1295228 G>A		Deleterious	TERT	Promoter SNV	hom _alt
WM4258- 2MP1MouseNum1596	TP53:NM_000546:exon7:c.673-1G>A		Likely Deleterious	TP53	splicing	hom _alt

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM4262CPLXMP2Mouse Num8592	ATM:NM_000051:exon33:c.C4964T:p.S1655F		VUS	ATM	nonsynonymous SNV	hom _alt
WM4262CPLXMP2Mouse Num8592	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	hom _alt
WM4262CPLXMP2Mouse Num8592	MYC:NM_002467:exon2:c.C85T:p.L29F		Likely Deleterious	MYC	nonsynonymous SNV	het
WM4262CPLXMP2Mouse Num8592	NRAS:NM_002524:exon2:c.G37C:p.G13R		Deleterious	NRAS	nonsynonymous SNV	het
WM4262CPLXMP2Mouse Num8592	PPP6C:NM_001123355:exon5:c.C451T:p.H151Y		Likely Deleterious	PPP6C	nonsynonymous SNV	het
WM4262CPLXMP2Mouse Num8592	PREX2:NM_024870:exon34:c.C4210T:p.H1404Y		VUS	PREX2	nonsynonymous SNV	het
WM4262CPLXMP2Mouse Num8592	PTPRD:NM_002839:exon32:c.C3599T:p.P1200L		Likely Deleterious	PTPRD	nonsynonymous SNV	het
WM4262CPLXMP2Mouse Num8592	TERT Chr5:1295228 G>A		Deleterious	TERT	Promoter SNV	het
WM4262CPLXMP2Mouse Num8592	WT1:NM_000378:exon1:c.C494T:p.S165F		Likely Deleterious	WT1	nonsynonymous SNV	het
WM4262MPIp5MouseNu m8539	ATM:NM_000051:exon33:c.C4964T:p.S1655F		VUS	ATM	nonsynonymous SNV	hom _alt
WM4262MPIp5MouseNu m8539	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	hom _alt
WM4262MPIp5MouseNu m8539	MYC:NM_002467:exon2:c.C85T:p.L29F		Likely Deleterious	MYC	nonsynonymous SNV	het
WM4262MPIp5MouseNu m8539	NRAS:NM_002524:exon2:c.G37C:p.G13R		Deleterious	NRAS	nonsynonymous SNV	het
WM4262MPIp5MouseNu m8539	PPP6C:NM_001123355:exon5:c.C451T:p.H151Y		Likely Deleterious	PPP6C	nonsynonymous SNV	het
WM4262MPIp5MouseNu m8539	PREX2:NM_024870:exon34:c.C4210T:p.H1404Y		VUS	PREX2	nonsynonymous SNV	het
WM4262MPIp5MouseNu m8539	PTPRD:NM_002839:exon32:c.C3599T:p.P1200L		Likely Deleterious	PTPRD	nonsynonymous SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM4262MP1p5MouseNum8539	TERT Chr5:1295228 G>A		Deleterious	TERT	Promoter SNV	het
WM4262MP1p5MouseNum8539	WT1:NM_000378:exon1:c.C494T:p.S165F		Likely Deleterious	WT1	nonsynonymous SNV	het
WM4264-1MP1MouseNum8243	ABL1:NM_005157:exon11:c.C2329T:p.R777X		VUS	ABL1	stopgain	het
WM4264-1MP1MouseNum8243	APC:NM_001127511:exon14:c.G4672T:p.E1558X		VUS	APC	stopgain	hom
WM4264-1MP1MouseNum8243	ATM:NM_000051:exon30:c.C4465T:p.R1489C		Likely Deleterious	ATM	nonsynonymous SNV	het
WM4264-1MP1MouseNum8243	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	het
WM4264-1MP1MouseNum8243	TERT Chr5:1295228 G>A		Deleterious	TERT	Promoter SNV	het
WM4264-1MP1MouseNum8243	TRRAP:NM_001244580:exon45:c.G6622T:p.V2208L		VUS	TRRAP	nonsynonymous SNV	het
WM4264-2MP1MouseNum9997	ABL1:NM_005157:exon11:c.C2329T:p.R777X		VUS	ABL1	stopgain	het
WM4264-2MP1MouseNum9997	ATM:NM_000051:exon30:c.C4465T:p.R1489C		Likely Deleterious	ATM	nonsynonymous SNV	het
WM4264-2MP1MouseNum9997	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymous SNV	het
WM4264-2MP1MouseNum9997	MAP2K2:NM_030662:exon2:c.A181G:p.K61E		VUS	MAP2K2	nonsynonymous SNV	het
WM4264-2MP1MouseNum9997	MET:NM_001127500:exon2:c.T721C:p.F241L		VUS	MET	nonsynonymous SNV	het
WM4264-2MP1MouseNum9997	TERT Chr5:1295228 G>A		Deleterious	TERT	Promoter SNV	het
WM4264-2MP1MouseNum9997	TRRAP:NM_001244580:exon45:c.G6622T:p.V2208L		VUS	TRRAP	nonsynonymous SNV	het
WM4280PLXMP1MouseNum9005	BRAF:NM_004333:exon15:c.GT1798AA:p.V600K		Deleterious	BRAF	nonsynonymous SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM4280PLXMP1MouseN um9005	GRIN2A:NM_001134407:exon12:c.G2364T:p.M788I		Likely Deleterious	GRIN2 A	nonsynonymo us SNV	het
WM4280PLXMP1MouseN um9005	IDH1:NM_005896:exon4:c.C394T:p.R132C		Deleterious	IDH1	nonsynonymo us SNV	het
WM4280PLXMP1MouseN um9005	NRAS:NM_002524:exon2:c.G34C:p.G12R		Deleterious	NRAS	nonsynonymo us SNV	het
WM4280PLXMP1MouseN um9005	PPP6C:NM_001123355:exon5:c.C451T:p.H151Y		Likely Deleterious	PPP6C	nonsynonymo us SNV	het
WM4280PLXMP1MouseN um9005	PREX1:NM_020820:exon28:c.C3632T:p.P1211L		Likely Deleterious	PREX 1	nonsynonymo us SNV	het
WM4280PLXMP1MouseN um9005	PTCH1:NM_001083602:exon2:c.G146C:p.G49A		Likely Deleterious	PTCH 1	nonsynonymo us SNV	het
WM4280PLXMP1MouseN um9005	TERT Chr5:1295228 G>A		Deleterious	TERT	Promoter SNV	het
WM4285MP1MouseNum9 571	ALK:NM_004304:exon28:c.A4115G:p.D1372G		Likely Deleterious	ALK	nonsynonymo us SNV	het
WM4285MP1MouseNum9 571	APC:NM_001127511:exon14:c.C6995T:p.S2332F		Likely Deleterious	APC	nonsynonymo us SNV	het
WM4285MP1MouseNum9 571	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM4285MP1MouseNum9 571	ERBB4:NM_005235:exon18:c.C2131T:p.R711C		Likely Deleterious	ERBB 4	nonsynonymo us SNV	het
WM4285MP1MouseNum9 571	FGFR2:NM_000141:exon3:c.A129C:p.Q43H		Likely Deleterious	FGFR 2	nonsynonymo us SNV	het
WM4285MP1MouseNum9 571	PTPRD:NM_002839:exon32:c.A3574G:p.I1192V		VUS	PTPR D	nonsynonymo us SNV	het
WM4285MP1MouseNum9 571	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM4335MP1MouseNum1 387	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM4335MP1MouseNum1 387	BRCA2:NM_000059:exon13:c.6942_6945del:p.T2314fs		Deleterious	BRCA 2	frameshift deletion	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM4335MP1MouseNum1 387	EGFR:NM_005228:exon18:c.G2065C:p.V689L		Likely Deleterious	EGFR	nonsynonymo us SNV	het
WM4335MP1MouseNum1 387	FBXW7:NM_033632:exon6:c.861+1G>A		Likely Deleterious	FBXW 7	splicing	het
WM4335MP1MouseNum1 387	GRM3:NM_000840:exon4:c.G2230A:p.D744N		VUS	GRM3	nonsynonymo us SNV	het
WM4335MP1MouseNum1 387	KDR:NM_002253:exon3:c.G289A:p.D97N		Likely Deleterious	KDR	nonsynonymo us SNV	het
WM4335MP1MouseNum1 387	MAP3K9:NM_033141:exon2:c.C523T:p.H175Y		VUS	MAP3 K9	nonsynonymo us SNV	het
WM4335MP1MouseNum1 387	PREX2:NM_024870:exon37:c.C4423T:p.P1475S		VUS	PREX 2	nonsynonymo us SNV	het
WM4335MP1MouseNum1 387	ROS1:NM_002944:exon35:c.G5713A:p.E1905K		VUS	ROS1	nonsynonymo us SNV	het
WM4335MP1MouseNum1 387	TP53:NM_000546:exon5:c.G524A:p.R175H		Deleterious	TP53	nonsynonymo us SNV	hom _alt
WM4336- 1MP1MouseNum555	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM4336- 1MP1MouseNum555	DCC:NM_005215:exon18:c.G2749A:p.E917K		Likely Deleterious	DCC	nonsynonymo us SNV	het
WM4336- 1MP1MouseNum555	PTEN:NM_001304717:exon4:c.684-1G>A		Likely Deleterious	PTEN	splicing	hom _alt
WM4360MP1MouseNum1 020	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM4360MP1MouseNum1 020	CDKN2A:NM_000077:exon2:c.151-1G>C		Likely Deleterious	CDKN 2A	splicing	hom _alt
WM4360MP1MouseNum1 020	ERBB4:NM_005235:exon13:c.C1565T:p.S522L		VUS	ERBB 4	nonsynonymo us SNV	het
WM4360MP1MouseNum1 020	NOTCH2:NM_024408:exon6:c.G958A:p.G320R		Likely Deleterious	NOTC H2	nonsynonymo us SNV	het
WM4360MP1MouseNum1 020	PDGFRA:NM_006206:exon12:c.G1702A:p.D568 N		Likely Deleterious	PDGF RA	nonsynonymo us SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX

Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM4360MP1MouseNum1 020	TERT Chr5:1295228 G>A		Deleterious	TERT	Promoter SNV	het
WM4388MP1MouseNum1 808	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM4388MP1MouseNum1 808	CDKN2A:NM_000077:exon1:c.28_40del:p.E10fs		Deleterious	CDKN 2A	frameshift deletion	het
WM4388MP1MouseNum1 808	TERT Chr5:1295228-1295229 GG>AA		Deleterious	TERT	Promoter SNV	het
WM4388MP1MouseNum1 808	TP53:NM_000546:exon6:c.C637T:p.R213X		Deleterious	TP53	stopgain	hom _alt
WM4390MP1MouseNum1 827	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM4390MP1MouseNum1 827	CCND2:NM_001759:exon2:c.C281T:p.P94L		VUS	CCND 2	nonsynonymo us SNV	het
WM4390MP1MouseNum1 827	GNAI1:NM_002067:exon4:c.C547T:p.R183C		Likely Deleterious	GNAI 1	nonsynonymo us SNV	het
WM4398MP1MouseNum1 722	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het
WM4398MP1MouseNum1 722	DCC:NM_005215:exon16:c.C2371T:p.H791Y		Likely Deleterious	DCC	nonsynonymo us SNV	hom _alt
WM4398MP1MouseNum1 722	MET:NM_001127500:exon9:c.C2181A:p.D727E		Likely Deleterious	MET	nonsynonymo us SNV	het
WM4398MP1MouseNum1 722	PRDM2:NM_012231:exon3:c.G106A:p.A36T		Likely Deleterious	PRDM 2	nonsynonymo us SNV	het
WM4398MP1MouseNum1 722	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het
WM4408MP1MouseNum1 965	ALK:NM_004304:exon29:c.C4774T:p.P1592S		Likely Deleterious	ALK	nonsynonymo us SNV	het
WM4408MP1MouseNum1 965	ARID1A:NM_006015:exon1:c.C581T:p.P194L		VUS	ARID1 A	nonsynonymo us SNV	hom _alt
WM4408MP1MouseNum1 965	BRAF:NM_004333:exon15:c.T1799A:p.V600E		Deleterious	BRAF	nonsynonymo us SNV	het

Table 4. TERT promoter mutations in Wistar's treatment-resistant PDX						
Sample	Variant	Comments	Call	Gene	Variant Type	Zyg
WM4408MP1MouseNum1 965	DCC:NM_005215:exon13:c.C1951G:p.Q651E		Likely Deleterious	DCC	nonsynonymo us SNV	hom _alt
WM4408MP1MouseNum1 965	TERT Chr5:1295250 G>A		Deleterious	TERT	Promoter SNV	het

Given the prevalence of *TERT* promoter mutations in melanoma and the potency of telomerase-directed 6-thio-dG therapy in inhibiting cell proliferation of telomerase activity-positive lung and colon cancer cells, the efficacy of 6-thio-dG in the *BRAF*-mutant melanoma subtype was tested. To that end, a panel of 12 *BRAF*-mutant human metastatic melanoma cell lines were treated with 6-thio-dG and BIBR 1532 for 9-12 days, respectively. Similarly, the anti-proliferative effect of 6-thio-dG in *BRAF*-mutant melanoma cell lines was observed (**FIG. 1B**).

Treatment of *BRAF*-mutant Melanoma Cells with 6-thio-dG Impairs Cell Viability and Tumor Growth. By investigating *BRAF*-mutant melanoma cell lines, the efficacy of 6-thio-dG was compared with that of the *BRAF* inhibitor, PLX4720. Another cohort of 16 *BRAF*-mutant melanoma cell lines was treated with 6-thio-dG and PLX4720 for 9 to 12 days, respectively. It was demonstrated that 6-thio-dG substantially inhibited cell proliferation. The efficacy of 6-thio-dG was comparable to and in some cases even superior to that of PLX4720 (**FIG. 3A**).

Treatment with 6-thio-dG over a shorter period of 5 days further revealed that 6-thio-dG significantly induced apoptosis and cell death in 9 of 12 *BRAF*-mutant melanoma cell lines (**FIG. 3B**). A375 melanoma cells was most sensitive to 6-thio-dG among all 12 *BRAF*-mutant melanoma cell lines (**FIG. 3B**). In a time-course experiment, it was shown that the induction of apoptosis started to occur as early as 48 hour post-treatment (**FIG. 3C**). A previous study showed that normal fibroblasts were not sensitive to 6-thio-dG, which is in line with the finding that 6-thio-dG did not impair the cell viability of normal epidermal melanocytes and keratinocytes (**FIG. 4**) (Mender *et al.*, 2015).

The induction of apoptosis and cell death prompted investigation of cells that had survived 6-thio-dG. The senescence-associated β -gal (SA- β -gal) staining of 4 representative *BRAF*-mutant melanoma cell lines suggested that the long-term treatment with 6-thio-dG triggered the induction of cellular senescence in cells that survived the initial killing by 6-thio-dG (**FIG. 3D**). Finally, using xenografts of the human metastatic melanoma 1205Lu cell line, it was shown that 6-thio-dG was able to significantly impair tumor growth (**FIG. 3E**).

Gene Expression and Protein Expression Signatures of 6-thio-dG. To gain mechanistic insights into the anti-proliferative effect of 6-thio-dG, A375 cells were treated with the control, BIBR 1532, and 6-thio-dG for 4 days, respectively. Integrated analyses were then carried out to profile the transcriptome with RNA sequencing (RNA-seq) and the functional proteome with reverse phase protein array (RPPA).

The differential expression analysis identified genes that were significantly down-regulated by 6-thio-dG, among which *CD274* (*PD-L1*) and *c-Myc* showed the highest degrees of change (**FIG. 5A**). To further unravel which signaling pathways were altered in A375 cells treated with 6-thio-dG, the hypergeometric differential analysis was carried out to identify the pathways that were statistically enriched among the significantly down-regulated genes. This analysis demonstrated that BioCarta gene sets related to cell cycle and telomere biology were among the top 10 ranked pathways (**FIGS. 5B-5C**). Furthermore, a complementary approach – single-sample gene set enrichment analysis (ssGSEA) – was utilized to verify that “cell cycle” and “telomere signaling” pathways were indeed suppressed by 6-thio-dG (**FIG. 5D**).

The analysis of RPPA data identified the top 30 significantly down-regulated proteins in A375 cells treated with 6-thio-dG. It was concluded that three major signaling pathways were altered in A375 cells treated with 6-thio-dG. They were (1) cell cycle: phospho-RB^{Ser807/811}, cyclin B1, CDK1, FOXM1, PLK1 and AURKB; (2) DNA damage response: 53BP1, ATM, ATR, CHK1 and CHK2; and (3) receptor tyrosine kinase signaling: VEGFR, PDGFR β , IGF-IR β , IGFBP2, phospho-STAT3^{Y705} and phospho-HER3^{Y1289} (**FIG. 5E**). Most of the down-regulated proteins were validated by western blotting and showed that these proteins were indeed inhibited in A375 cells treated with 6-thio-dG but not BIBR 1532 or another telomerase inhibitor GRN163L (**FIGS. 5F-5G**).

Because the computational analysis indicated that the cell cycle pathway is altered, A375 cells that express the “fluorescent, ubiquitination-based, cell-cycle indicators Fucci, version 2” (A375^{Fucci2}) were further exploited in order to visualize cell cycle progression. The time-lapse imaging showed that A375^{Fucci2} cells treated with 6-thio-dG over 42 hours were arrested at the G₂/M checkpoint followed by cell death (data not shown).

6-thio-dG Down-regulates PLK1, PDGFR β , ARID1A and AXL at the Protein Level. To identify signaling protein molecules that were commonly altered in melanoma cells treated with 6-thio-dG, RPPA was carried out to profile 3 *BRAF*-mutant melanoma cell lines, including A375, UACC-903 and WM9. The analysis of RPPA data showed that PLK1, PDGFR β , ARID1A and AXL were significantly down-regulated at the protein level in all three cell lines (**FIG. 6A**), which was further validated with A375 cells treated with 6-thio-dG by western blotting (**FIG. 6B**).

Notably, AXL and PDGFR β are known to mediate intrinsic and acquired resistance of *BRAF*-mutant melanoma cells to MAPKi (Muller *et al.*, 2014; Nazarian *et al.*, 2010; Tirosh *et al.*, 2016). Indeed, the analysis of RPPA data showed that PDGFR β was up-regulated in A375 cells that were intrinsically resistant to the short-term treatment with MAPKi (**FIG. 6C-6D**),

which was validated by the western blotting of A375 cells treated with MAPKi (**FIG. 6E**). Moreover, ARID1A, PDGFR β and PLK1 but not AXL were up-regulated in A375 and WM9 cells that acquired resistance to PLX4720 (**FIG. 6F**). Similarly, AXL and PDGFR β were up-regulated in UACC-903 cells that acquired resistance to PLX4720 or the combination of
 5 PLX4720 and PD0325901 (**FIG. 6F**).

This data prompted further experimentation to test whether the combination of 6-thio-dG with the BRAF inhibitor could delay or abrogate the acquisition of therapy resistance to BRAFi. Indeed, the combination of 6-thio-dG with GSK2118436 (GSK436; dabrafenib) substantially inhibited the emergence of clones in all three *BRAF*-mutant melanoma cell lines
 10 that acquired resistance to GSK2118436 (**FIG. 6G**).

6-thio-dG Significantly Impairs Cell Viability, Proliferation and Tumor Growth of MAPKi Resistant Melanoma Cells. AXL and PDGFR β are known to mediate the acquired resistance to MAPKi, therefore the efficacy of 6-thio-dG in MAPKi-resistant melanoma cell lines was tested, due to its ability to inhibit ARID1A, AXL, PDGFR β and PLK1 and to
 15 overcome the intrinsic drug resistance.

It was observed that 6-thio-dG significantly induced apoptosis and cell death in LOX-IMVI BR cells that acquired resistance to the BRAFi (**FIG. 7A**). Treatment of LOX-IMVI BR cells with 6-thio-dG for 120 hours led to progressive telomere shortening (**FIG. 7B**). Compared to the control, 6-thio-dG also induced DNA damage (**FIGS. 7C-7D**) and led to an increase in
 20 telomere dysfunction-induced foci (TIFs) that can be observed as co-localization of a specific γ -H2AX antibody (double strand DNA damage marker) with an *in situ* telomere specific hybridization probe (FITC-conjugated telomere sequence (TTAGGG)₃ peptide nucleic acid) (**FIGS. 7C and 7E**).

RNA-seq was carried out to profile the transcriptome of LOX-IMVI BR cells treated
 25 with 6-thio-dG and found that the ssGSEA demonstrated that “cell cycle” and “telomere signaling” pathways were diminished. This is in line with data obtained from A375 cells treated with 6-thio-dG (**FIG. 7F**).

Similar to A375 cells treated with 6-thio-dG, the analysis of RPPA data showed that, three major signaling pathways were altered in LOX-IMVI BR cells treated with 6-thio-dG.
 30 They were (1) cell cycle: phospho-RB^{Ser807/811}, cyclin B1, CDK1, FOXM1, PLK1, AURKB, Cdc25C, and p-Cdc2^{Y15}; (2) DNA damage response: 53BP1 and CHK1; (3) receptor tyrosine kinase signaling: VEGFR and PDGFRb (**FIG. 7G**). In addition, other functionally important proteins were also down-regulated, including p-YAP^{S127}, p-FAK^{Y397}, p-4E-BP1^{S65}, and β -catenin (**FIG. 7G**). To validate the RPPA data, western blotting was used to demonstrate that

expression levels of AXL and PLK1 were decreased in LOX-IMVI BR cells treated with 6-thio-dG by (FIG. 7H).

Treatment of ten melanoma cell lines that acquired resistance to PLX4720 and one melanoma cell line (WM1366 MR) that acquired resistance to the MEK inhibitor, MEK162 with 6-thio-dG for 12 days impaired their viabilities (FIGS. 7I and 8A). The RPPA profiling of eight MAPKi-resistant cell lines treated with 6-thio-dG revealed similar observations to those made in LOX-IMVI BR cells (FIG. 8B).

It was found that treatment of A375^{Fucci2}-BR cells that acquired resistance to the BRAF inhibitor or A375^{Fucci2}-CR cells that acquired resistance to the combination of BRAF and MEK inhibitors also led to the arrest of cell cycle progression and the induction of cell death as demonstrated by the time-lapse imaging (data not shown).

Furthermore, it was shown that 6-thio-dG significantly impaired the *in vivo* growth of three xenografts derived from WM9 BR, LOX-IMVI BR and UACC-903 BR cells (FIGS. 7J-7L). 1205Lu, LOX-IMVI BR and UACC-903 BR xenografts treated with 6-thio-dG *in vivo* were profiled with RPPA. The analysis of RPPA data confirmed the inhibition of AXL, ARID1A and PDGFR β in these xenografts (FIGS. 8C-8D).

The Association of *TERT* Expression with Overall Survival and Therapy Resistance. Studies were extended from cell lines to human melanoma by analyzing RNA-seq data of 470 TCGA skin cutaneous melanomas and genome-wide gene expression microarray data of 104 melanomas, 9 nevi, and 7 normal skin samples (GEO accession number GSE46517). Initially, the focus was on the enrichment of two telomere transcriptional gene signatures - “packaging of telomere ends” and “telomere maintenance”. Four additional gene sets were included as benchmarks that are uniquely expressed in melanoma, including “lysosome”, “melanogenesis”, “BRAF targets” and “MEK targets” (Barretina *et al.*, 2012; Cancer Genome Atlas, 2015; Gao *et al.*, 2015; Kabbarah *et al.*, 2010).

The ssGSEA revealed that “packaging of telomere ends” and “telomere maintenance” were highly enriched in a substantial subset of TCGA melanomas (FIG. 9A). Additionally, the inventors demonstrated that these two telomere transcriptional gene signatures were highly enriched in primary and metastatic melanomas but not in normal skin samples or benign nevi (FIG. 9B). Importantly, the Kaplan-Meier survival analysis revealed that TCGA patients whose melanomas have higher enrichment scores of telomere transcriptional gene signatures are associated with a worse overall survival outcome compared to those whose tumors had lower enrichment scores (FIG. 9C).

In addition to treatment-naïve human melanoma, paired pre-, on- and post-treatment

tumor biopsies derived from patients with metastatic melanoma who were treated with targeted therapies or immune checkpoint blockade therapies were analyzed. The ssGSEA identified that “packaging of telomere ends” and “telomere maintenance” were highly enriched in a subset of post-treatment tumor biopsies procured at the time of disease progression on BRAF inhibitor or the combination therapy of BRAF and MEK inhibitors compared to paired pre-treatment tumor biopsies (**FIGS. 9D** and **FIGS. 10A-10C**). It was shown that there was a greater than a 2-fold increase in expression of *TERT* in 7 out of 21 on-treatment tumor biopsies and 3 out of 6 post-treatment tumor biopsies, respectively (**FIG. 10D** and **Table 6**).

Table 6. Targeted Therapy Patient's Clinical Information

PT	Mutation	RX	Dose (daily)	Response	Time To Progression (months)
2	BRAF	vemurafenib	1920mg	PR (-60.5%)	8.5
4	BRAF	vemurafenib	1920mg	PR (-56%)	3.5
5	BRAF	vemurafenib	1920mg	SD (-27%)	6.5
6	BRAF	dabrafenib + trametinib	dabrafenib: 300mg, trametinib: 2mg	PR (-59.9%)	21
7	BRAF	dabrafenib + trametinib	dabrafenib: 300mg, trametinib: 2mg	CR (-100%)	17, ongoing 47 months
8	BRAF	dabrafenib + trametinib	dabrafenib: 300mg, trametinib: 1.5mg	PR (-30%)	3
9	BRAF	dabrafenib + trametinib	dabrafenib: 300mg, trametinib: 2mg	PR (-45%)	7
10	BRAF	dabrafenib + trametinib	dabrafenib: 300mg, trametinib: 2mg	SD (-13%)	3
11	BRAF	dabrafenib + trametinib	dabrafenib: 300mg, trametinib: 2mg	PR (-80%)	10
12	BRAF	dabrafenib + trametinib	dabrafenib: 300mg, trametinib: 2mg	PR (-88.9%)	12, stopped at 20 months
13	BRAF	dabrafenib + trametinib	dabrafenib: 300mg, trametinib: 2mg	PR (-57.9%)	9, stroke
15	BRAF	vemurafenib	1920mg	SD (-16.5%)	6
16	BRAF	dabrafenib + trametinib	dabrafenib: 300mg, trametinib: 1mg	SD (-19.5%)	11
19	BRAF	dabrafenib + trametinib	dabrafenib: 300mg, trametinib: 2mg	PR (-48.7%)	ongoing, 36 months
20	BRAF	vemurafenib	1920mg	PR (-51.2%)	5
22	BRAF	dabrafenib + trametinib	dabrafenib: 300mg, trametinib: 2mg	PR (-42%)	3
24	BRAF	vemurafenib	1920mg	PR (-53%)	2
25	BRAF	dabrafenib + trametinib	dabrafenib: 150mg, trametinib: 2mg	PR (-64%)	3
34	BRAF	LGX818 + MEK162	LGX818: 600mg, MEK162: 45mg	PR (-48.6%)	stopped drug after 14 months, PD at 15 months

Table 6. Targeted Therapy Patient's Clinical Information					
PT	Mutation	RX	Dose (daily)	Response	Time To Progression (months)
35	BRAF	LGX818 + MEK162	LGX818: 600mg, MEK162: 45mg	SD (-22.8%)	stopped after 7 months, PD at 10 months
38	BRAF	vemurafenib	1920mg	SD (-24.9%)	4.3
40	BRAF	vemurafenib	1920mg	SD	stopped drug after 6 months, PD at 9 months
42	BRAF	LGX818 + MEK162	LGX818: 400mg, MEK162: 60mg	PR (-76.1%)	PD at 13 months
43	BRAF	vemurafenib	1920mg	CR (-81.5%)	13.4

To establish a direct link between the activation of telomere signaling axis and resistance to immune checkpoint blockade therapies, RNA-seq data of 14 post-treatment tumor biopsy specimens derived from patients with metastatic melanoma who were treated with ipilimumab were first analyzed (Chiappinelli *et al.*, 2016; Snyder *et al.*, 2014). By comparing tumor biopsy specimens derived from patients experiencing “no clinical benefit” to those derived from patients experiencing “long-term clinical benefit” (**Table 7**), genes were identified that were differentially expressed between “no clinical benefit” and “long-term clinical benefit” subgroups and then GSEA was carried out in order to identify pathways that were positively associated with the phenotype of “no clinical benefit”. Interestingly, among those highly ranked gene sets is the “BioCarta TEL pathway” that is comprised of genes related to telomeres, telomerase, cellular aging, and immortality (**FIG. 9E**).

Table 7. MSKCC Immunotherapy Patients' Clinical Information						
PatientID	Histology	Response	Run	PrePost	Gender	BioSite
CR1509	Melanoma	LB	First	post	F	cutaneous
CR7623	Melanoma	NB	First	post	M	cutaneous
CR9699.1	Melanoma	LB	First	post	M	cutaneous
CR9699.2	Melanoma	LB	First	post	M	cutaneous
NR1867	Melanoma	NB	First	pre	M	acral
NR3549	Melanoma	NB	First	pre	M	cutaneous
NR4631	Melanoma	NB	Second	post	M	cutaneous
NR4810	Melanoma	NB	First	post	F	cutaneous
NR4949	Melanoma	NB	First	post	F	unknown
NR5784	Melanoma	NB	First	pre	F	cutaneous
NR8727	Melanoma	NB	First	pre	M	cutaneous
NR9449	Melanoma	NB	Second	post	F	cutaneous
NR9521	Melanoma	NB	Second	post	M	cutaneous
NR9705	Melanoma	NB	Second	post	F	acral
SD0346	Melanoma	LB	First	post	F	cutaneous
SD1494.1	Melanoma	LB	First	pre	M	cutaneous
SD1494.2	Melanoma	LB	First	pre	M	cutaneous
SD2051	Melanoma	NB	First	pre	F	acral
SD2056	Melanoma	LB	First	pre	F	cutaneous
SD5038	Melanoma	NB	First	post	M	cutaneous
SD5118.1	Melanoma	NB	First	post	F	acral
SD5118.2	Melanoma	NB	First	post	F	acral
SD6336.1	Melanoma	LB	First	post	M	cutaneous
SD6336.2	Melanoma	LB	First	post	M	cutaneous
SD6494.1	Melanoma	NB	First	post	F	unknown
SD6494.2	Melanoma	NB	First	post	F	unknown
SD7357.1	Melanoma	NB	First	post	F	unknown
SD7357.2	Melanoma	NB	First	post	F	unknown

RNA-seq of 31 paired pre-, on- and/or post-treatment tumor biopsies derived from 12 patients who were treated with various immune checkpoint blockade therapies were carried

out. The best response for most of patients was progressive disease. The ssGSEA identified that “packaging of telomere ends” and “telomere maintenance” were highly enriched in 7 out of 12 patients’ on- or post-treatment tumor biopsies (**FIG. 11**). For instance, patient #39 was treated with pembrolizumab with the best response being progressive disease. Prior to
5 pembrolizumab, this patient progressed on vemurafenib, IL-2, ipilimumab, and dabrafenib plus trametinib. It was observed that “telomere maintenance” and “packaging of telomere ends” were highly enriched in this patient’s on-treatment tumor biopsy compared to the paired pre-treatment tumor biopsy (**FIG. 9F** and **Table 8**).

Table 8. MGH Immunotherapy Patients' Clinical Information								
MGH Patient ID	Date	SampleID	Mutation	RX-1	RX-2	Response	start_date	notes
27	3/8/2012	27_030812	BRAF mut	BRAFⁱ->PD1	post-BRAFⁱ (479 days); pre-PD1	PD	6/1/2013	
27	7/2/2013	27_070213			post-BRAFⁱ (960 days); post-PD1 (31 days)			
39	3/31/2014	39_033114	BRAF mut	Vem->IL2->IPI->dab+tra->PD1	post-BRAFⁱ (393 days); post-IL2 (388 days); post-IPI (153 days); pre-dab+tra; pre-PD1	PD (Mixed response: PR of bulky nodes but PD soft tissue)	Vem: 3/3/13; IL2:3/18/13; IPI: 10/29/13-12/30/13; dab+tra: 7/2/14; PD1: 8/4/14	
39	8/25/2014	39_082514			post-BRAFⁱ (540 days); post-IL2 (535 days); post-IPI (300 days); post-dab+tra (54 days); post-PD1 (21 days)	X5		

Table 8. MGH Immunotherapy Patients' Clinical Information								
MGH Patient ID	Date	SampleID	Mutation	RX-1	RX-2	Response	start_date	notes
39	10/31/2014	39_103114			post-BRAF ⁱ (607 days); post-IL2 (602 days); post-IPI (367 days); post-dab+tra (121 days); post-PD1 (88 days)			
42	10/17/2014	42_101714	BRAF mut	IPI- >dab+tra- >PD1	post-IPI (176 days); post-dab+tra (64 days); pre-PD1	X2	IPI: 4/24/14, 4th dose 6/27/14; dab+tra: 8/14/14-10/14; PD1: 10/17/14-1/9/15 PD	
42	11/24/2014	42_112414			post-IPI (214 days); post-dab+tra (102 days); post-PD1 (38 days)	PD		
42	12/30/2014	42_123014			post-IPI (250 days); post-dab+tra (138 days); post-PD1 (74 days) [PD after 84 days]			
51	8/14/2013	51_081413			pre-PDL1			

Table 8. MGH Immunotherapy Patients' Clinical Information								
MGH Patient ID	Date	SampleID	Mutation	RX-1	RX-2	Response	start_date	notes
51	4/18/2014	51_041814		PD-L1	post-PDL1 (224 days)	SD (-4.8%) / slow PD		
62	10/2/2013	62_100213	GNAQ mut	IPI->PD1->CDK4/6i+MEKi	pre-IPI; pre-PD1; pre-CDK4/6i+MEKi	slow, steady PD	IPI: 10/4/13-12/4/13 PD; PD1: 5/24/14-7/8/14; CDK4/6+MEKi: 1/7/15 - SD	
62	5/27/2014	62_052714			post-IPI (235 days); post-PD1 (3 days); pre-CDK4/6i+MEKi			
62	7/8/2014	62_070814			post-IPI (277 days); post-PD1 (45 days); pre-CDK4/6i+MEKi			
98	2/5/2014	98_020514	NA	PD1->IPI	post-PD1 (83 days); pre-IPI	PR (-62.1%), mixed response	NIVO: 11/14/13-1/23/14; IPI: 2/6/14-4/10/14; maintenance NIVO: 5/14-	
98	3/3/2014	98_030314			post-PD1 (109 days); post-IPI (25 days)			

Table 8. MGH Immunotherapy Patients' Clinical Information								
MGH Patient ID	Date	SampleID	Mutation	RX-1	RX-2	Response	start_date	notes
98	5/15/2014	98_051514			post-PD1 (182 days); post-IPI (98 days)			
98	6/11/2015	98_061115			post-PD1 (574 days); post-IPI (490 days)			
115	3/18/2014	115_031814		IPI->PD1->PD1+KIR	pre-IPI; pre-PD1; pre-KIR	PR (-37.7%) / PD CNS	IPI (3/24/14, 3 cycles, PD1: 5/25/14 PD), PD1+KIR (8/25/14-, PD CNS, PR elsewhere, remaining on trial)	
115	4/15/2014	115_041514			post-IPI (22 days); pre-PD1; pre-KIR			
115	6/5/2015	115_060515			post-IPI (438 days); post-PD1 (376 days); post-KIR (284 days)			
148	6/5/2014	148_060514	NA	PD1+KIR	pre-PD1; pre-KIR	PD	PD1 / KIR: 6/5/14-11/14/14 PD	
148	12/31/2014	148_123114			post-PD1 (209 days); post-KIR (209 days)			

Table 8. MGH Immunotherapy Patients' Clinical Information								
MGH Patient ID	Date	SampleID	Mutation	RX-1	RX-2	Response	start_date	notes
208	9/10/2014	208_091014	NA	IPI->PD1	pre-IPI; pre-PD1	PD, mixed response	prior limb perfusion; IPI: 09/10/14 C1d1-11/12/14 4 doses, mixed response, PD 03/15; PD1: 03/11/15-	
208	10/22/2014	208_102214			post-IPI (42 days); pre-PD1			
208	3/11/2015	208_031115-1			post-IPI (182 days); pre-PD1	X2		
208	3/11/2015	208_031115-2			post-IPI (182 days); pre-PD1	X2		
208	5/13/2015	208_051315			post-IPI (245 days); post-PD1 (63 days)			
272	12/19/2014	272_121914	NA	IPI->PD1	pre-IPI	PR (eventually)	IPI: 12/19/14-2/25/15 (4 cycles); PD1: 3/20/15	Patient was slow progressor (had initial growth), but after Tx tumor went away (responder)
272	2/4/2015	272_020415			post-IPI (47 days); pre-PD1			
422	9/28/2015	422_092815			pre-IPI; pre-PD1			

Table 8. MGH Immunotherapy Patients' Clinical Information									
MGH Patient ID	Date	SampleID	Mutation	RX-1	RX-2	Response	start_date	notes	
422	11/5/2015	422_110515							
PDL002	6/18/2012	PDL002_061812	BRAF mut	PDL1	post-IP1; post-PDL1	SD(-0.7%)	6/18/2012		
PDL002	8/1/2012	PDL002_080112			post-PDL1 (44 days)				
PDL002	2/12/2013	PDL002_021213							

6-thio-dG Significantly Impairs the Cell Viability, Proliferation and Tumor Growth of Melanoma Cells that are Resistant to Immune Checkpoint Inhibitors.

Having demonstrated the efficacy of 6-thio-dG in inhibiting the *in vivo* growth of MAPKi-resistant tumors, the ability of 6-thio-dG to inhibit the *in vivo* growth of melanoma cells that are resistant to immune checkpoint inhibitors was investigated. Two short-term primary cultures, T708-13-456-3-3 and T708-13-456-5-3, were established, respectively, from two *BRAF*^{V600E} melanoma breast metastases that were surgically removed from a patient who progressed on sequential therapies including radiation therapy, ipilimumab, temozolomide, and pembrolizumab. Next, a short-term primary culture, 15-1761-1-2 derived from a metastatic melanoma in a left axillary lymph node, was established. These cells had a *NRAS*^{G61R} mutation that was derived from a patient who first progressed on pembrolizumab and subsequently on the combination of ipilimumab plus nivolumab. Finally, PDXs from two *NRAS*^{Q61R} brain metastases derived from a patient with metastatic melanoma were established, and two PDXs-derived cell lines, WM4265-1 and WM4265-2, were subsequently established. This patient progressed on sequential therapies, including cisplatin, vinblastine, temozolomide, interleukin-2, IFN α -2b, ipilimumab, and pembrolizumab.

In addition to therapy-resistant human melanoma, there was access to two derivatives of the mouse melanoma cell line B16. The first was 499 cell line that was resistant to radiation therapy and anti-CTLA-4; and the second cell line was JB2 that differs from 499 in which *PD-L1* was knocked out (Benci *et al.*, 2016). Those therapy-resistant cells including 13-456-3-3, 13-456-5-3, WM4265-1, WM4265-2, 499 and JB2 were treated with 6-thio-dG and it was observed that the prolonged treatment with 6-thio-dG for 12 days markedly inhibited *in vitro* cell proliferation (**FIG. 12A**).

Furthermore, anti-tumor activity of 6-thio-dG in five xenografts, including WM4265-2, 13-456-3-3, 15-1761-1-2, 13-456-5-3 and 499 was shown (**FIGS. 12B-12F**). Three representative xenografts were profiled that had been treated with 6-thio-dG using RPPA and showed that therapy-resistant markers, AXL, ARID1A and PLK1 were down-regulated in 13-456-5-3 xenografts (**FIG. 12G**); mTOR-S6 signaling axis was down-regulated in 13-456-3-3 xenografts (**FIG. 12H**); and the therapy-resistant marker, ARID1A and S6 signaling axis were down-regulated in WM4265-2 xenografts (**FIG. 12I**). Similar observations were also made in 13-456-3-3, 13-456-5-3, WM4265-1 and WM4265-2 cells that were treated with 6-thio-dG *in vitro* (**FIG. 13**). In summary, these results demonstrate that 6-thio-dG significantly impaired the *in vivo* growth of xenografts derived from various therapy-resistant melanoma models.

6-thio-dG Significantly Impairs Cell Viability, Proliferation and Tumor Growth of Therapy-Resistant Mouse Pancreatic Cancer Cells and Human Ovarian Cancer Cells.

This work was further extended to non-melanoma therapy-resistant cancer cells in order to evaluate the efficacy of 6-thio-dG more broadly. The mouse pancreatic cancer cell line G43 was established from mouse pancreatic tumors harboring mutations in *KRAS* and *P53* that progressed on radiation therapy and subsequently ipilimumab. The *in vitro* treatment of G43 cells with 6-thio-dG for 9 days impaired cell viability (**FIG. 14A**). It was tested if 6-thio-dG had *in vivo* anti-tumor activity and therefore xenografts of G43 tumors were treated with 6-thio-dG for 15 days. It was demonstrated that 6-thio-dG significantly delayed the growth of G43 tumors ($p < 0.0001$) (**FIG. 14B**). To identify which proteins were down-regulated in G43 cells treated with 6-thio-dG, RPPA profiling was conducted and demonstrated that ARID1A was down-regulated in G43 cells treated with 6-thio-dG *in vitro* (**FIG. 14C**) which was also found in therapy-resistant melanoma cells treated with 6-thio-dG. The analysis of RPPA data revealed that AXL, IGF-IR β and VEGFR were down-regulated in G43 tumors treated with 6-thio-dG *in vivo* (**FIG. 14D**) which was also found in therapy-resistant melanoma cells treated with 6-thio-dG.

Additionally, the efficacy of 6-thio-dG was tested using two human ovarian cancer cell lines, PEO4 and PEO1-CR. PEO4 is a derivative line of *BRCA1/2*-mutant PEO1 that regains homologous recombination by BRCA reversion mutation. PEO1 was sensitive to carboplatin, whereas PEO4 was intrinsically resistant to carboplatin and PEO1-CR acquired resistance to carboplatin (**FIGS. 14E-14G**). Importantly, all three cell lines were sensitive to 6-thio-dG after the 5-day treatment (**FIGS. 14H-14J**).

A short-term primary culture, WO-24-2 from a therapy-resistant human ovarian cancer, was also established. The WO-24-2 tumor was resected from a patient with high grade serous ovarian cancer who underwent an interval debulking surgery after receiving neoadjuvant chemotherapy with platinum/taxane and subsequently progressed on platinum chemotherapy. Immunofluorescence staining of PAX8 and cytokeratin 7 confirmed that these were indeed human ovarian cancer cells (**FIG. 14K**) (George *et al.*, 2017). It was demonstrated that the WO-24-2 short-term primary culture was resistant to carboplatin (**FIG. 14L**). Finally, WO-24-2 cells were treated with 6-thio-dG at 5 μ M and it was found that cell viability was substantially inhibited (**FIG. 14M**).

Taken together, this data highlights the impressive anti-tumor activity of 6-thio-dG in non-melanoma therapy-resistant pancreatic and ovarian cancer cells, suggesting that 6-thio-dG

may be used as a viable therapeutic approach in additional preclinical models of therapy-resistant cancers.

* * * * *

5 All of the compositions and methods disclosed and claimed herein can be made and
executed without undue experimentation in light of the present disclosure. While the
compositions and methods of this disclosure have been described in terms of preferred
embodiments, it will be apparent to those of skill in the art that variations may be applied to
the compositions and/or methods and in the steps or in the sequence of steps of the method
10 described herein without departing from the concept, spirit and scope of the disclosure. More
specifically, it will be apparent that certain agents that are both chemically and physiologically
related may be substituted for the agents described herein while the same or similar results
would be achieved. All such similar substitutes and modifications apparent to those skilled in
the art are deemed to be within the spirit, scope and concept of the disclosure as defined by the
15 appended claims.

V. References

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference:

5

Barretina *et al.* *Nature* 483, 603-607, 2012.

Benci *et al.* *Cell* 167, 1540-1554 e1512, 2016.

Cancer Genome Atlas, N. *Cell* 161, 1681-1696, 2015.

Chiappinelli *et al.* *Cell* 164, 1073, 2016.

10 Gao *et al.* *Nat Med* 21, 1318-1325, 2015.

George *et al.* *JCI Insight* 2, e89760, 2017.

Kabbarah *et al.* *PLoS One* 5, e10770, 2010.

Kim *et al.* Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models. *Clin Cancer Res.* 2016.

15 Mender *et al.* *Cancer Discov* 5, 82-95, 2015.

Muller *et al.* *Nat Commun* 5, 5712, 2014.

Nazarian *et al.* *Nature* 468, 973-977, 2010.

Snyder *et al.* *N Engl J Med* 371, 2189-2199, 2014.

Tirosh *et al.* *Science* 352, 189-196, 2016.


CLAIMS

What Is Claimed Is:

1. A method of treating a subject with cancer comprising administering to said subject a therapeutically effective amount of 6-thio-2'-deoxyguanosine (6-thio-dG), wherein
5 cells of said cancer are telomerase-positive and exhibit (a) one or more *TERT* promoter mutations, and/or (b) enriched telomere transcriptional signature(s).
2. A method of treating a subject with melanoma comprising administering to said subject a therapeutically effective amount of 6-thio-2'-deoxyguanosine (6-thio-dG), wherein
10 melanoma is resistant to an immunotherapy and/or MAPKi therapy.
3. The method of claim 1, wherein said subject has had disease progression during or after platinum-based therapy, radiotherapy, immunotherapy and/or MAPKi therapy.
- 15 4. The method of claims 2 or 3, wherein the immunotherapy is an immune checkpoint inhibitor, such as anti-CTLA4 therapy or anti-PD1 therapy.
5. The method of claims 2 or 3, wherein the MAPKi therapy is an anti-MEK therapy, an anti-Raf therapy, and anti-p38 MAPK therapy, and anti-JNK therapy, and anti-ERK
20 therapy, or an anti MNK therapy, such as vemurafenib, sorafenib, dabrafenib, trametinib, selumetinib, losapimod, GSK2118436, PD0325901, PLX4032 or PLX4720.
6. The method of claims 1 or 2, wherein the cancer is a B-Raf-mutated cancer.
25
7. The method of claim 6, wherein the B-Raf-mutated cancer is a *Braf*^{V600} mutant.
8. The method of claim 1, wherein the cancer is a lung cancer, a melanoma, pancreatic cancer or an ovarian cancer.
30
9. The method of claims 1 or 2, wherein said enriched telomere transcription signature is a telomere maintenance signature or a packaging of telomere ends signature.

10. The method of claims 1 or 2, wherein a therapeutically effective amount of 6-thio-dG is between about 0.5 mg/kg and 5.0 mg/kg.
- 5 11. The method of claims 1 or 2, wherein 6-thio-dG is administered more than once.
12. The method of claim 11, wherein 6-thio-dG is administered twice daily, daily, every other day, twice a week, weekly, every other week, every three weeks, or monthly.
- 10 13. The method of claims 1 or 2, wherein 6-thio-dG is administered systemically, such as orally or intravenously.
14. The method of claims 1 or 2, wherein 6-thio-dG is administered intratumorally, or local or regional to a tumor site.
- 15 15. The method of claims 1 or 2, wherein the subject is a human subject.
16. The method of claims 1 or 2, wherein the subject is a non-human mammalian subject.
- 20 17. The method of claims 1 or 2, further comprising treating said subject with a second cancer therapy.
18. The method of claim 17, wherein said second cancer therapy is an immunotherapy, such as ipilimumab and nivolumab or combination of ipilimumab and nivolumab, a
25 radiotherapy, a neoadjuvant chemotherapy (such as platinum/taxane), a toxin therapy, a hormonal therapy or surgery.
19. The method of claim 17, wherein said second cancer therapy is administered at the same time or after 6-thio-dG.
- 30 20. The method of claim 17, wherein said second cancer therapy is administered before 6-thio-dG.

21. The method of claims 1 or 2, wherein treatment results in one or more of impaired cancer cell viability, cancer cell apoptosis, cancer cell senescence in surviving cancer cells, and progressively shortened telomeres in surviving cancer cells.
- 5 22. The method of claims 1 or 2, wherein treatment results in one or more of increased subject survival, reduced tumor burden, reduction in primary tumor size, reduced metastasis, induction of remission, reduced subject hospitalization and increased subject comfort.
- 10 23. The method of claims 1 or 2, further comprising assessing a cancer cell from said subject for one or more of (a) *TERT* promoter mutation, (b) enriched telomere transcriptional signature(s), (c) increased AXL expression, (d) increased PDGFR β expression, and/or (e) one or more B-Raf mutations.
- 15 24. The method of claim 23, wherein said enriched telomere transcription signature is a telomere maintenance signature or a packaging of telomere ends signature.
25. The method of claims 1 or 2, wherein said cancer is recurrent, metastatic and/or multi-drug resistant.



FIGS. 1A-1B




FIG. 2





FIG. 3A



FIGS. 3B-3E




FIG. 4







FIG. 5A




FIGS. 5B-5D




FIGS. 5E-5G




FIGS. 6A-6G




FIGS. 7A-7F




FIGS. 7G-7L



FIGS. 8A-8B








FIG. 8B
CONTINUED







FIG. 8B
CONTINUED




FIGS. 8C-8D




FIGS. 9A-9B





FIGS. 10A-10C






FIG. 11






FIG. 11
CONTINUED



FIGS. 12A-12F



FIGS. 12G-12H




FIG. 12I




FIG. 13






FIG. 13
CONTINUED



FIGS. 14A-14D



FIGS. 14E-14M

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 17/34706

A. CLASSIFICATION OF SUBJECT MATTER
 IPC(8) - A61K 31/522, A61K 31/7076 (2017.01)
 CPC - G01N 33/5743, C12N 15/1135, A61K 31/33, C12N 2320/31

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History Document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History Document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History Document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No. .
Y	US 2014/0303239 A1 (THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM) 09 October 2014 (09.10.2014) claims 1, 2, 16, para [0012], [0033], [0043], [0045], [0046], [0047] [0052], [0056], [0057], [0059], [0060], [0061], [0071], [0090],	1-25
Y	VINAGRE et al., Frequency of TERT promoter mutations in human cancers. Nat Commun, July 2013, Vol 4, pp 1-6. Especially abstract, p 2 col 1 para 4; p 4 col 1 para 3;	1, 3-25
Y	HUGO et al., Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell, September 2015, Vol 162, No 6, pp 1271-1285. Especially abstract, p 1273 col 1 para 3; p 1271 col 2 para 3;	2-5

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

11 August 2017

Date of mailing of the international search report

06 SEP 2017

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
 P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
 PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 17/34706

Box No. 1 Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
- a. ☐ forming part of the international application as filed:
☐ in the form of an Annex C/ST.25 text file.
☐ on paper or in the form of an image file.
- b. ☐ furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
- c. ☒ furnished subsequent to the international filing date for the purposes of international search only:
☒ in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
☐ on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2. ☒ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments: